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ABSTRACT 
HCV afflicts many millions of people globally, and antiviral therapies are often 
ineffective and intolerable.  The Food and Drug Administration approved the HCV 
protease inhibitors telaprevir and boceprevir in May 2011, marking an important 
milestone in anti-HCV research over the past two decades.  Nevertheless, severe drug 
side effects of combination therapy – flu-like symptoms, depression and anemia – limit 
patient adherence to treatment regimens.  The acquisition of resistance challenges the 
long-term efficacy of antiviral therapies, including protease inhibitors, as suboptimal 
dosing allows for the selection of drug resistant viral variants.  A better understanding of 
the molecular basis of drug resistance is therefore central to developing future generation 
protease inhibitors that retain potency against a broader spectrum of HCV strains.  
To this end, my research characterizes the molecular basis of drug resistance 
against HCV protease inhibitors.  Chapter II defines the mode of substrate recognition by 
the common volume shared by NS3/4A substrate products – the substrate envelope.  
Chapter III then correlates patterns of drug resistance to regions where drugs protrude 
from the substrate envelope.  Lastly, Chapter IV elucidates the molecular underpinnings 
of resistance against four leading protease inhibitors – telaprevir, danoprevir, vaniprevir 
and MK-5172 – and provides practical approaches to designing novel drugs that are less 
susceptible to resistance.  I ultimately hope my work appeals to the broader biomedical 
community of virologists, medicinal chemists and clinicians, who struggle to understand 
HCV and other human pathogens in the face of rapid disease evolution. 
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PREFACE 
Most will not find the patience or time to read my dissertation cover-to-cover.  
Thus each research chapter reads as an independent manuscript, comprising 
comprehensive background, discussion and references.  The unintended consequences of 
such formatting, however, are periodic redundancies in content or theme.  Nevertheless, I 
hope that my dissertation – in its current form – more practically conveys the 
implications my research in its broader medical context. 
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CHAPTER I 
INTRODUCTION  
1
 HEPATITIS C VIRUS 
Since the discovery of Hepatitis C Virus (HCV) in 1989 (1), the World Health 
Organization estimates that the virus infects 3% of the global population and that 3–4 
million new infections occur annually (2).  About 80% of all infections evade immune 
detection and persist chronically in patients (3).  HCV most commonly spreads through 
direct blood contact (4), though most infections go unrecognized due to mild disease 
symptoms (3, 5).  Clinicians most often establish HCV diagnoses by screening patients 
for exposure risks rather than overt disease symptoms (6).  In fact, approximately three-
quarters of infected individuals are not formally diagnosed with the disease (7).  An 
estimated 15–30% of chronically infected patients develop liver cirrhosis over a period of 
three decades (8).  Most patients remain unaware of HCV infection until advanced-stage 
disease – a leading cause of cirrhosis, hepatocellular carcinoma and liver transplantation 
in the United States (9, 10).   
HCV replicates rapidly in untreated patients, producing about one trillion virus 
particles daily (11, 12).  Inaccuracy of viral replication accounts for the large genetic 
diversity among the six major genotypes globally, each subcategorized into several 
subtypes and many strains.  Genotype 1 viruses cause the majority of all infections, 
predominating in North America, South America and Europe, while genotype 2 viruses 
are less common throughout the world.  Genotype 3 viruses mainly afflict Southeast Asia 
and certain other countries, such as Russia.  Genotype 4 viruses predominate in the 
Middle East, Egypt and central Africa.  Genotype 5 viruses account for most infections in 
South Africa, while genotype 6 viruses are endemic to Asia (13). 
2
 Until recently, anti-HCV therapies comprised yearlong treatment with ribavirin 
and pegylated interferon-α, requiring strict patient adherence with weekly clinical 
appointments (6).  In May 2011, the Food and Drug Administration approved the 
protease inhibitors telaprevir and boceprevir for use in combination with ribavirin and 
pegylated interferon-α.  Nevertheless, severe drug side effects – flu-like symptoms, 
depression and anemia – limit patient adherence to treatment regimens.  The high cost 
and adverse effects of antiviral drugs prohibit many clinicians from offering therapy to 
patients lacking the social, financial and emotional support systems necessary for strict 
adherence (14).  Moreover, combination therapy with ribavirin and pegylated interferon-
α cures only half of patients, depending on both host cell and viral genetic factors (15-
19).  Thus current anti-HCV treatment options are insufficient, and better antiviral 
therapies, diagnostic tools and vaccines must be developed and implemented throughout 
the world. 
3
 THE HCV LIFECYCLE 
A hepacivirus of the Flaviviridae family, HCV contains an RNA genome with a 
single open reading frame flanked by 5′ and 3′ untranslated regions (UTRs).  The 
positive-sense genome is packaged in an icosahedral scaffold of Core proteins, which are 
enveloped by phospholipid membranes derived from the host cell endoplasmic reticulum.  
The viral envelope glycoproteins, E1 and E2, insert within the outer envelope and 
facilitate virus fusion to human hepatocytes (Figure 1.1).  Specifically, E1 and E2 
mediate fusion to the host cell membrane receptors Tetraspanin (CD81) and Scavenger 
receptor class B type I (SR-B1) (20, 21).  The co-expression of CD81 and SR-B1 alone 
are insufficient for efficient HCV fusion, however, and additional factors further mediate 
the process, such as Claudin 1, Occludin, Low-density lipoprotein receptors and 
glycosaminoglycans (22-24).  After stable fusion to the host cell surface, the virus enters 
the cytosol by clathrin-mediated endocytosis (25).  The acidic endoplasmic environment 
facilitates virus fusion to the endosomal membrane, leading to the release of the RNA 
genome into the cytoplasm (26). 
Host cell machinery then translates the HCV genome in a cap-independent 
manner as a 3011-residue polyprotein, which is subsequently processed by host cell and 
viral proteases into structural (Core, E1, E2, p7) and non-structural (NS2, NS3, NS4A, 
NS4B, NS5A, NS5B) components (27).  The structural proteins are inserted into the 
endoplasmic reticulum lumen and cleaved into functional units by host signal peptidases.  
The non-structural proteins – most exhibiting enzymatic functions – are translated along 
the cytosolic side of the endoplasmic reticulum and processed into functional units by 
4
Figure 1.1:  The HCV lifecycle.  HCV virions fuse to human hepatocytes through 
interactions with CD81 and SR-B1 and enter by clathrin-mediated endocytosis; virus 
particles uncoat in the cytosol and host cell machinery translates the genomic RNA along 
the endoplasmic reticulum membrane; viral replication proceeds from a single duplex 
RNA template; nascent virions then assemble in the endoplasmic reticulum and are 
trafficked through the Golgi secretary pathway for extracellular release.
5
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 two viral proteases, NS2/3 and NS3/4A (28).  After translation of the necessary proteins, 
the viral replication complex forms along the cytoplasmic membrane, characterized as 
membranous webs by electron microscopy (29).  The viral RNA-dependent RNA 
polymerase, NS5B, initiates HCV replication by synthesizing a single, negative-sense 
strand from the positive-sense RNA genome.  NS5B copies the resulting duplex RNA 
molecule to generate many positive-sense progeny genomes (30-32).  The HCV genomes 
then enter the endoplasmic reticulum and are packaged into virus particles, which are 
subsequently trafficked through the Golgi secretory pathway for extracellular release. 
7
 THE BIFUNCTIONAL NS3 PROTEIN 
The NS3 protein comprises 631 amino acids organized into two functional 
domains (Figure 1.2), which are each essential for viral replication (33, 34).  The N-
terminal protease domain, a chymotrypsin-like serine protease, heterodimerizes with the 
viral NS4A protein for efficient proteolytic activity (35).  The C-terminal helicase 
domain, a super family II DEAD-box helicase (36), uses ATP hydrolysis to drive duplex 
RNA unwinding.  Although the protease and helicase domains remain active in isolation 
(37-41), each domain depends on the other for optimal catalytic efficiency.  The presence 
of the protease domain, for example, enhances the efficiency of duplex RNA unwinding 
(38, 41).  Active duplex RNA unwinding also inhibits the concurrent hydrolysis of viral 
substrate peptides (42), suggesting that the protease domain may support RNA unwinding 
in a proteolytically-inhibited conformation.  The helicase domain was also shown to 
enhance NS3/4A proteolytic efficiency (40), although others groups report comparable 
catalytic efficiencies between the full-length NS3 protein and protease domain alone (39, 
43).  Thus potential domain interdependency may influence NS3 protease and helicase 
activities, as well as HCV replication, evolution and virulence. 
The NS3-mediated processing of viral and host cell targets is central to HCV 
replication and its evasion of the human innate immune response.  NS3/4A protease 
cleaves four known sites in the viral polyprotein at junctions 3-4A, 4A4B, 4B5A and 
5A5B.  NS3 first cleaves the 3-4A junction in cis and subsequently forms a heterodimer 
with cofactor NS4A.  The NS3/4A complex then cleaves the remaining three sites in 
trans (35).  Schechter and Berger first formulated the nomenclature for peptide cleavage 
8
Figure 1.2:  Crystal structure of the bifunctional HCV NS3 protein.  The NS3 
helicase domain (pink) packs against the protease domain (cyan) with the essential 
cofactor NS4A shown in blue.  The C-terminus of the helicase domain (magenta) – the 
post-cleavage product substrate 3-4A – binds to the protease active site with the catalytic 
triad residues shown in yellow.
9
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 positions in 1967:  they defined the cleavage site between residues P1–P1' (represented 
N-terminal to C-terminal) and designated upstream and downstream amino acids by 
incremental numbering (44).  Notably, the four NS3/4A cleavage sites share little 
sequence homology spanning P6–P4', except of an acid at P6, cysteine or threonine at P1 
and serine or alanine at P1' (Table 1.1). 
The NS3/4A protease also disrupts the innate immune response to viral infection 
by inactivating the transcription factors Interferon regulatory factor 3 (IRF-3) and 
Nuclear factor κB (NF-κB) (45, 46).  The detection of viral RNA upregulates these host 
cell transcription factors through two distinct pathways, involving either Toll-like 
receptor 3 (TLR3) or Retinoic acid-inducible gene I (RIG-I) (47, 48).  NS3/4A protease 
disrupts the TLR3 and RIG-I cascades by cleaving the essential adaptor proteins Toll-
interleukin-1 receptor domain-containing adaptor-inducing interferon-β (TRIF) and 
Mitochondrial antiviral signaling protein (MAVS), respectively (46, 49).  The TRIF and 
MAVS cleavage sites share little sequence homology with other viral substrates: TRIF 
contains cysteine at P1 and serine at P1', while MAVS contains glutamate at P6 and 
cysteine at P1 (Table 1.1).  Notably, TRIF contains a tract of eight proline residues 
spanning P13–P6, which may play a unique role in the recognition process (50).  Thus 
NS3/4A protease recognizes these viral and host cell sequences specifically as substrates 
despite their large sequence divergence, obscuring the molecular determinants of 
substrate recognition. 
11
 Table 1.1.  Genotype 1a primary cleavage sequences of NS3/4A substrates. 
Substrate P6 P5 P4 P3 P2 P1 P1' P2' P3' P4' 
TRIF P(8) S S T P C S A H L 
MAVS E R E V P C H R P S 
3-4A D L E V V T S T W V 
4A4B D E M E E C S Q H L 
4B5A E C T T P C S G S W 
5A5B E D V V C C S M S Y 
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 EMERGING ANTIVIRAL THERAPIES 
Since the protease domain was first crystallized in 1997 (51), pharmaceutical 
companies have invested considerable resources in developing NS3/4A protease 
inhibitors.  Early drug design efforts were hampered by the relatively shallow, featureless 
architecture of the protease active site.  The eventual observation of N-terminal product 
inhibition served as a stepping-stone for the discovery of more potent hexapeptide 
inhibitors (52, 53).  Over the past decade, pharmaceutical companies have further 
developed these lead compounds by evaluating the effect of functional moieties at 
positions P4–P1′ on antiviral potency (54-60).  The resulting protease inhibitor class 
contains both linear and macrocyclic drug candidates.  Macrocyclic drugs are constrained 
to adopt the secondary structure of bound hexapeptides, forcing trans geometry of the 
P2–P3 amide bond (61, 62).  Linear drugs achieve similar geometry with bulky P3 
substituents, which disfavor cis P2–P3 bonds (63).  Most protease inhibitors include 
either P1–P1′ ketoamide moieties, which form reversible covalent bonds with the 
protease, or sulfonamide groups.   
Boehringer Ingelheim first demonstrated protease inhibitor efficacy in the 2005 
clinical trial with its leading drug, ciluprevir (64, 65).  Though later discontinued due to 
cardiotoxicity (66), ciluprevir provided proof-of-principle that protease inhibitors could 
achieve potent antiviral effects.  Several other companies, including Vertex, Merck, 
Bristol-Myers Squibb, Roche, Tibotec and Medavir, have since developed promising 
clinical candidates (Figure 1.3).  Most notably, boceprevir (Merck) and telaprevir 
(Vertex) – linear ketoamide compounds – were approved in May 2011 by the Food and 
13
Figure 1.3:  HCV NS3/4A protease inhibitors in development.  The protease inhibitor 
class contains both linear and macrocyclic compounds.  Ciluprevir first demonstrated 
efficacy in clinical trials, but was later discontinued due to cardiotoxicity.  Telaprevir and 
boceprevir were approved by the Food and Drug Administration in May 2011 for use in 
combination with ribavirin and pegylated interferon-α.  Many other drug candidates are 
in various stages of clinical development.
14
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 Drug Administration, marking an important milestone in anti-HCV research and drug 
development over the past two decades.  Other drugs are also advancing through clinical 
trials:  (i) the macrocyclic sulfonamide TMC-435 (Tibotec/Medavir) in phase 3, (ii) the 
macrocyclic sulfonamide drugs danoprevir (Roche) and vaniprevir (Merck) in phase 2, 
(iii) the linear sulfonamide BMS-650032 (Bristol-Myers Squibb) and linear carboxylate 
BI201335 (Boehringer Ingelheim) in phase 2, and (iv) the macrocyclic sulfonamide MK-
5172 (Merck) in phase 1 clinical trials.  Thus more anti-HCV treatment options will 
become available to patients in the coming decade, led by many clinical candidates in the 
protease inhibitor class. 
Pharmaceutical companies have also developed nucleoside and non-nucleoside 
inhibitors of the NS5B polymerase.  Nucleoside inhibitors mimic the natural viral 
substrates of the RNA-dependent RNA polymerase and act as terminators in nascent 
RNA chains.  Though these drugs display marked antiviral potencies, severe adverse 
effects have halted the development of several, such as R1626 (Roche) (67, 68).  
Nevertheless, some nucleoside inhibitors, such as RG7128 (Roche/Pharmasset) and PSI-
7977 (Pharmasset), have advanced into phase 2 clinical trials.  Non-nucleoside inhibitors 
bind to allosteric sites away from the NS5B active site and induce inhibited enzyme 
conformations.  Though resistance mutations often limit the efficacy of these compounds 
(69), many non-nucleoside inhibitors are in early phases of human clinical trials, such as 
filibuvir (Pfizer), BI207127 (Boehringer Ingelheim), GS-9190 (Gilead) and ABT-333 
(Abbott) (70). 
Difficulties in propagating HCV in cell culture have hampered the identification 
16
 of other drug targets and delayed the discovery of novel antiviral drugs.  Nearly two 
decades after the discovery of HCV, researchers in 2005 established the first cell culture 
systems that robustly supported viral replication in human-derived cells (71, 72).  The 
improved understanding of HCV biology has led to the identification of many other 
antiviral targets, including the viral proteins NS5A, NS4B and p7 (73-75).  The viral 
NS5A protein plays an essential role in viral replication, assembly and release.  The 
highly potent NS5A inhibitor BMS-790052 (Bristol-Myers Squibb) is showing promise 
in phase 2 clinical trials (69).  In addition, pharmaceutical companies are targeting host 
cell proteins central to HCV replication, such as cyclophilins, which regulate HCV 
replication by chaperoning protein folding.  The cyclophilin inhibitor alisporivir 
(Novartis) demonstrated efficacy against several HCV genotypes during monotherapy 
and in combination with pegylated interferon-α (76).  Thus diverse antiviral therapies are 
emerging in the collective effort to combat HCV in the face of its global disease burden. 
17
 PROTEASE INHIBITOR RESISTANCE 
The absence of proofreading activity makes the HCV NS5B RNA-dependent 
RNA polymerase highly inaccurate.  Misincorporation of bases during replication causes 
high mutation rates in all viral proteins (77).  Some of these mutations are neutral, while 
others alter the viability of the virus.  Patients infected with HCV for a period of time will 
develop heterogeneous virus populations, known as quasispecies (78-80).  As patients 
begin antiviral treatment, selective drug pressures favor resistant viral strains, particularly 
in the setting of monotherapy (81).  To reduce the likelihood of resistance, treatment 
regimens utilize multiple antiviral agents simultaneously that limit viral evolution by 
distinct mechanisms. 
Nevertheless, combination therapies with ribavirin and pegylated interferon-α are 
only effective for a subset of patients, depending on both human and viral genetic factors 
(15-19).  Moreover, sustained treatment adherence remains a critical predictor for 
treatment outcome, as suboptimal dosing allows for the selection of drug resistant viral 
variants (82).  Adverse drug effects, including flu-like symptoms, depression and anemia, 
are commonly reported and often hinder the successful completion of full-dose treatment 
regimens (82, 83).  Though high treatment completion rates are reported in clinical trials, 
these patients are routinely screened prior to enrollment and actively supported 
throughout therapy to maximize adherence (84).  In the actual clinical setting, however, 
several small cohort studies suggest completion rates as low as 50%, highlighting the 
influence of disease co-morbidities, socioeconomic status, emotional support and related 
factors on treatment outcome (85, 86).  Furthermore, dominant polymerase and protease 
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 inhibitor resistance mutations have been detected in a minority of treatment naïve 
individuals, suggesting that drug resistant strains pre-exist and may be directly 
transmissible (87).  Thus despite the benefits of combination therapy in limiting viral 
evolution, the emergence of drug resistance still challenges the long-term efficacy of 
antiviral therapies.  
Indeed, the rapid rise of resistance has reduced the efficacy of many potent 
protease inhibitors (Table 1.2).  Most notably, mutations at residues R155, A156 and 
D168 – located in the protease P2 subsite – confer resistance against many leading drugs.  
In particular, the mutations A156T/V and R155K confer high-level resistance against 
nearly all drugs reported in the literature (88-93).  Resistance mutations at residues V36, 
T54 and V170 are more distant from the protease site and implicate indirect effects, such 
as protein dynamics, in drug binding.  In addition, the S489L mutation – within the NS3 
helicase domain – confers resistance against danoprevir, suggesting that the helicase 
domain may influence drug binding (94).  Drug resistance occurs when mutations in the 
target disrupt inhibitor binding while preserving target function (95).  Thus drug resistant 
protease variants retain hydrolytic efficiency, highlighting the need to understand the 
molecular underpinnings of resistance in the context of substrate recognition.  Ultimately, 
structural studies may help elucidate the mechanistic pathways of resistance, facilitating 
additional approaches for developing protease inhibitors that are equally potent but less 
susceptible to resistance. 
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 Table 1.2.  Reported sites of drug resistance mutations 
Res. Mutations Drugs 
V36 A, M, L, G Boceprevir, telaprevir 
Q41 R Boceprevir, danoprevir 
F43 S, C, V, I Boceprevir, telaprevir, danoprevir, TMC435 
V55 A Boceprevir 
T54 A, S Boceprevir, telaprevir 
Q80 K, R, H, G, L TMC435 
S138 T Danoprevir, TMC435† 
R155 K, T, I, M, G, L, S, Q Boceprevir, telaprevir, danoprevir, ciluprevir, TMC435 
A156 V, T, S, I, G Boceprevir, telaprevir, danoprevir, ciluprevir, TMC435 
V158 I Boceprevir 
D168 A, V, E, G, N, T, Y, H, I Danoprevir, ciluprevir, TMC435 
V170 A Boceprevir, telaprevir 
M175 L Boceprevir 
†-TMC435 displays reduced activity against S138T, but the mutation was not observed in selection 
experiments. 
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 INSIGHTS FROM HIV-1 PROTEASE 
The acquisition of HIV-1 protease inhibitor resistance provides important insights 
into the HCV drug resistance.  The nine HIV-1 protease inhibitors approved by the Food 
and Drug Administration contain similar functional groups and form similar interactions 
with the protease (95-97).  The natural viral substrates – though highly diverse in primary 
sequence – bind to the active site in a common three-dimensional volume, termed the 
substrate envelope (96).  The superposition of drug and substrate complexes reveals that 
most resistance mutations occur where the inhibitors protrude from the substrate 
envelope (Figure 1.4) (95).  Resistance mutations in regions outside the substrate 
envelope – space not occupied by viral substrates – selectively prevent drug binding with 
minimal effect on substrate processing.   
In theory, inhibitors designed to fit within the substrate envelope will be less 
susceptible to resistance, as mutations preventing drug binding will concurrently disrupt 
the binding of viral substrates.  To test this theory, novel protease inhibitors were 
designed to fit within the substrate envelope based on the scaffold of the highly potent 
drug darunavir (98-101).  The effects of chemical substituents on antiviral potency were 
evaluated at several positions on the darunavir scaffold.  After several rounds of 
optimization, ten compounds exhibited greater antiviral activity than darunavir in cell 
culture infected with highly resistant HIV-1 strains (Figure 1.5).  Thus the substrate 
envelope-based design strategy led to highly potent, broadly active HIV-1 protease 
inhibitors, and may also prove useful in developing of robust therapies against other 
rapidly evolving pathogens, such as HCV. 
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Figure 1.4:  HIV-1 protease substrate and inhibitor envelopes.  (A) The HIV-1 
protease substrate envelope, depicted in blue, is defined as the consensus vdW volume 
shared by any four of the six viral substrates.  (B) The consensus vdW shared by the 
protease inhibitors defines the inhibitor envelope, shown in red.  (C) Superposition of the 
inhibitor envelope reveals regions where the drugs collectively protrude from the 
substrate envelope, which coincide with sites of drug resistance mutations.
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Figure 1.5:  HIV-1 substrate envelope-based inhibitor design.  Ten drug candidates – 
designed to fit within the substrate envelope – retain high potency against a panel of drug 
resistant HIV strains relative to darunavir (black circles), the most potent drug currently 
available to patients.
24
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 SCOPE OF THESIS 
I must first address gaps in the current body of HCV literature before pursuing 
substrate enveloped-based drug design approaches.  At the conception of this research, no 
crystal structures were available of the NS3/4A protease in complex with authentic viral 
substrates or post-cleavage products.  In addition, despite several drugs in clinical trials, 
only the crystal structure of boceprevir with genotype 1b protease was available.  My 
research addresses these gaps by determining crystal structures of NS3/4A protease 
bound to authentic substrate products and leading protease inhibitors.  Together these 
studies elucidate the molecular underpinnings of drug resistance, and may someday 
provide a more direct path for developing novel drugs that retain activity against a 
broader spectrum of HCV strains. 
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 ABSTRACT 
Hepatitis C NS3/4A protease is a prime therapeutic target responsible for cleaving 
the viral polyprotein at junctions 3-4A, 4A4B, 4B5A and 5A5B, and two host cell adapter 
proteins of the innate immune response, TRIF and MAVS.  In this study, NS3/4A crystal 
structures of both host cell cleavage sites are determined and compared to the crystal 
structures of viral substrates.  Two distinct protease conformations are observed and 
correlate with substrate specificity:  (i) 3-4A, 4A4B, 5A5B and MAVS, which are 
processed more efficiently by the protease, form extensive electrostatic networks when in 
complex with the protease, and (ii) TRIF and 4B5A – containing polyproline motifs in 
their full-length sequences – do not form electrostatic networks in their crystal 
complexes.  These findings provide mechanistic insights into NS3/4A substrate 
recognition, which may assist in a more rational approach to inhibitor design in the face 
of the rapid acquisition of resistance. 
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 INTRODUCTION 
Hepatitis C virus (HCV) is a genetically diverse hepacivirus of the Flaviviridae 
family infecting over 180 million people worldwide (1).  The positive-sense, single-
stranded RNA genome encodes a single polyprotein, which is translated along the 
endoplasmic reticulum.  Host cell and viral proteases cleave the viral polyprotein into 
structural (C, E1, E2) and non-structural components (p7, NS2, NS3, NS4A, NS4B, 
NS5A, NS5B) (2).  The NS3/4A protein, a bifunctional protease/helicase enzyme formed 
by the non-covalent association of NS3 and NS4A, hydrolyzes four known sites along the 
viral polyprotein, thereby liberating non-structural proteins essential for viral replication.  
Previous kinetic data suggest that the first cleavage at the 3-4A junction occurs in cis, 
while processing of the remaining junctions occurs in trans (3, 4).  Interestingly, 
heterodimerization with NS4A is essential for the cleavage of junction 4B5A.  These 
viral substrates share little sequence similarity, except for an acid at P6, cysteine or 
threonine at P1 and serine or alanine at P1' (Table 2.1).  We have shown that the diverse 
set of NS3/4A substrate sequences are recognized in a conserved three-dimensional 
shape, defining a consensus van der Waals (vdW) volume, or substrate envelope (5).  
This conserved mode of substrate recognition regulates polyprotein processing and thus 
the biology of HCV replication. 
In addition to its essential role in processing the viral polyprotein, NS3/4A 
protease also confounds the innate immune response to viral infection by disrupting 
activation of the transcription factors interferon regulatory factor 3 (IRF-3) and nuclear 
factor κB (NF-κB) (6, 7).  The detection of viral RNA induces these transcription factors 
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 Table 2.1.  Genotype 1a primary cleavage sequences of NS3/4A substrates. 
Substrate P6 P5 P4 P3 P2 P1 P1' P2' P3' P4' 
TRIF P(8) S S T P C S A H L 
MAVS E R E V P C H R P S 
3-4A D L E V V T S T W V 
4A4B D E M E E C S Q H L 
4B5A E C T T P C S G S W 
5A5B E D V V C C S M S Y 
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 through two distinct pathways, involving signaling through Toll-like receptor 3 (TLR3) 
or retinoic acid-inducible gene I (RIG-I) (8, 9).  NS3/4A protease disrupts the TLR3 and 
RIG-I cascades by cleaving the essential adaptor proteins Toll-interleukin-1 receptor 
domain-containing adaptor-inducing interferon-β (TRIF) and mitochondrial antiviral 
signaling protein (MAVS), respectively (7, 10).  The TRIF and MAVS cleavage sites 
share little sequence homology with other viral substrates: TRIF contains cysteine at P1 
and serine at P1', while MAVS contains glutamate at P6 and cysteine at P1 (Table 2.1).  
Notably, in place of an acid at position P6, TRIF consists of a tract of eight proline 
residues spanning P13–P6, which has been previously implicated as part of the substrate 
recognition motif for NS3/4A (11).  The NS3-mediated processing of both viral and host 
cell targets is central to the interplay between HCV replication and the innate immune 
response, thus highlighting the importance of better elucidating the mechanisms of 
substrate recognition.  
Despite great efforts devoted to the development of NS3/4A protease inhibitors, 
the rapid rise of drug resistance in human clinical trials has limited the efficacy of the 
most promising drug candidates.  Drug resistance mutations in the protease emerge as 
molecular changes that prevent the binding of drugs, but still permitting the recognition 
and cleavage of substrates.  A more detailed understanding of the molecular details 
underlying substrate recognition is therefore critical for explaining patterns of drug 
resistance and for designing novel drugs that are less susceptible to resistance.  Here we 
analyze crystal structures of NS3/4A protease in complex with N-terminal products of 
viral substrates 3-4A, 4A4B, 4B5A and 5A5B.  TRIF and MAVS crystal complexes 
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 further reveal that these host cell products bind to the protease active site in a conserved 
three-dimensional manner similar to that of the viral products.  Notably, extensive 
electrostatic networks involving protease residues D81, R155, D168 and R123 form in 
product complexes 3-4A, 4A4B, 5A5B and MAVS while these networks are absent in the 
4B5A and TRIF product complexes.  Short peptides corresponding to the immediate 
cleavage sequences of TRIF and 4B5A have significantly weaker affinities for NS3/4, 
which correlate with their inability to form of such electrostatic networks with the 
protease.  Taken together, our findings support previous biochemical studies implicating 
the role of polyproline II helices in TRIF cleavage by NS3/4A (11), and provide a 
structural basis for future studies aimed at better elucidating the detailed mechanism 
NS3/4A substrate recognition and cleavage. 
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 MATERIALS AND METHODS 
Mutagenesis and gene information 
The HCV genotype 1a NS3/4A protease gene described in a Bristol-Meyers 
Squibb patent (12) was synthesized by GenScript and cloned into the pET28a expression 
vector (Novagen).  The gene encodes a highly soluble form of the NS3/4A protease 
domain as a single-chain, with 11 core amino acids of NS4A located at the N-terminus.  
The inactive S139A protease variant was subsequently constructed using the QuikChange 
site-directed mutagenesis kit from Stratagene and sequenced by Davis Sequencing for 
confirmation. 
Viral substrate and peptide product purchase and storage 
Thirty milligrams of each substrate peptide and the corresponding N-terminal 
cleavage product (TRIF and MAVS) were purchased from 21st Century Biochemicals 
(Marlboro, MA).  The TRIF and MAVS peptides were synthesized as a 13mer (P13–P1) 
and 7mer (P7–P1), respectively.  The C-termini of all substrate peptides were blocked 
with amide groups.  All peptides were stored as solids at −20ºC and dissolved in DMF to 
a final concentration of 50–100mM for crystallization trials. 
Expression and purification of NS3/4A protease constructs 
NS3/4A expression and purification were carried out as described previously (12, 
13).  Briefly, transformed BL21(DE3) E. coli cells were grown at 37ºC and induced at an 
optical density of 0.6 by the addition of 1mM IPTG.  Cells were harvested after 5 hours 
of expression, pelleted and frozen at −80ºC for storage.  Cell pellets were thawed, 
resuspended in 5mL/g of resuspension buffer (50mM phosphate buffer at pH 7.5, 500mM 
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 NaCl, 10% glycerol, 2mM β-ME) and lysed with a cell disruptor.  The soluble fraction 
was retained, applied to a nickel column (Qiagen), washed with resuspension buffer, and 
eluted with resuspension buffer supplemented with 200mM imidazole.  The eluant was 
dialyzed overnight (MWCO 10kD) to remove the imidazole and the his-tag was 
simultaneously removed with thrombin treatment.  The nickel-purified protein was then 
flash-frozen and stored at −80ºC for up to six months. 
Crystallization of product complexes and apo enzyme 
For crystallization, the protein solution was thawed, concentrated to ~3mg/mL 
and loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer 
(25mM MES at pH 6.5, 500mM NaCl, 10% glycerol, 30µM zinc chloride, and 2mM 
DTT).  The protease fractions were pooled and concentrated to 20–25mg/mL with an 
Amicon Ultra-15 10kD device (Millipore).  The concentrated samples were either used 
for crystallization of apo structure or incubated for one hour with 2–20 molar excess of 
substrate product TRIF or MAVS.  Diffraction-quality crystals were obtained overnight 
by mixing equal volume of concentrated protein solution with precipitant solution (20–
26% PEG-3350, 0.1M sodium MES buffer at pH 6.5, and 4% ammonium sulfate) in 24-
well VDX hanging drop trays. 
Data collection and structure solution  
Crystals large enough for data collection were flash-frozen in liquid nitrogen for 
storage.  The TRIF, MAVS and apo crystals were mounted under constant cryostream 
and X-ray diffraction data were collected at Advanced Photon Source LS-CAT 21-ID-F, 
BioCARS 14-BMC and our in-house RAXIS IV X-ray system, respectively.  Diffraction 
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 intensities of product complexes were indexed, integrated and scaled using the program 
HKL2000 (14).  All structure solutions were generated using simple isomorphous 
molecular replacement with PHASER (15).  The B chain model of viral substrate product 
4A4B (3M5M) (5) was used as the starting model for all structure solutions.  Initial 
refinement was carried out in the absence of modeled ligand, which was subsequently 
built in during later stages of refinement.  Upon obtaining the correct molecular 
replacement solutions, the phases were improved by building solvent molecules using 
ARP/wARP (16).  Subsequent crystallographic refinement was carried out within the 
CCP4 program suite with iterative rounds of TLS and restrained refinement until 
convergence was achieved (17). The final structures were evaluated with MolProbity (18) 
prior to deposition in the protein data bank.  5% of the data was reserved for the free R-
value calculation to limit the possibility of model bias throughout the refinement process 
(19).  Interactive model building and electron density viewing was carried out using the 
program COOT (20). 
Double-difference plots and global analysis 
Double-difference plots were computed as described previously (21).  Briefly, the 
atomic distances were calculated between each Cα of a given protease molecule and 
every other Cα in the same molecule.   The differences of these Cα-Cα distances were 
then calculated between each pair of protease molecules and plotted as a contour graph 
for visualization.  These analyses allowed for effective structural comparisons without the 
biases associated with superimpositions and space group differences.  Double-difference 
plots were used to determine the structurally invariant regions of the protease, consisting 
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 of residues 32–36, 42–47, 50–54, 84–86 and 140–143.  Structural superimpositions were 
carried out in PyMOL (22) using the Cα atoms of these residues for all protease 
molecules.  The apo structure was used as the reference structure for the alignments of 
the TRIF and MAVS product complexes.  The Cα RMSD for each residue was 
subsequently calculated to access the degree of structural variation throughout the 
protein.  The B-factor column of a representative structure was replaced with these values 
and used to generate the rainbow color spectrum to visualize these variations. 
The viral substrate envelope 
All active site alignments were performed with PyMOL using the Cα atoms of 
protease residues 137–139 and 154–160.  For each alignment, the B chain of complex 
4A4B was used as the reference structure.  The viral substrate envelope – representing 
the consensus vdW volume shared by any three of the four viral substrate products – was 
computed as described previously using the full-length NS3/4A structure (1CU1) (23) 
and product complexes 4A4B (3M5M), 4B5A (3M5N) and 5A5B (3M5O) (5).  
NMR spectroscopy and data processing 
NMR data were recorded using 650µL of 390µM [U-15N] NS3/4A protease (95% 
H2O/5% D2O, 25mM sodium phosphate at pH 7.2, 150mM KCl, 5µM zinc chloride, and 
1mM TCEP).  Backbone 1H and 15N resonance assignments of NS3/4A protease were 
kindly provided by Herbert Klei of Bristol-Myers Squibb, and confirmed using nuclear 
Overhauser enhancement spectroscopy (NOESY) experiments.  Backbone 1H and 15N 
resonance assignments of NS3/4A protease bound to the N-terminal cleavage product of 
substrate 4A4B were obtained from the assignment of the free protein by following the 
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 chemical shift changes upon titration of the ligand.  All experiments were performed at 
298K using a Varian Inova spectrometer operating at 600 MHz (14.1 T).  Spectra were 
processed using nmrPipe (24) and Sparky (25). 
Binding of the unlabeled peptide corresponding to the N-terminal cleavage 
product of substrate 4A4B to [U-15N] NS3/4A protease was monitored using a series of 
two-dimensional 15N-1H HSQC spectra collected at increasing concentrations of the 
peptide to a final concentration of 2.5mM.  The change of the cross-peak positions for 
NS3/4A residues was recorded as a function of titrated peptide concentration.  The 
normalized change in the chemical shift was calculated for each protease residue using 
the following equation: 
 
Δ = ΔδH
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where Δδ is the chemical shift change observed between the free and bound states, γ  is 
the gyromagnetic ratio, and the subscript indicates either 1H or 15N nuclei.  The b-factors 
for each residue of the apo enzyme crystal structure were then replaced by the maximal 
chemical shift changes from the titration data.  The crystal structure was colored in 
PyMOL (22) according to the chemical shift magnitudes to graphically depict the 
locations of the shifting residues. 
VdW contact energy 
VdW contact energies between protease residues and peptide products were 
computed using a simplified Lennard-Jones potential as described previously (26).  
Briefly, the Lennard-Jones potential (Vr) was calculated for each protease-product atom 
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 pair where r, ε and σ represent the interatomic distance, vdW well depth and atomic 
diameter, respectively: 
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Vr was computed for all possible protease-product atom pairs within 5Å, and potentials 
for non-bonded pairs separated by less than the distance at the minimum potential were 
equated to −ε.  Using this simplified potential value for each non-bonded protease-
product atom pair, the total vdW contact energy (ΣVr) was computed for each peptide 
residue.  For graphical convenience, VdW energy indexes were then calculated by 
multiplying the raw values by a factor of –10. 
Fluorescence polarization 
For fluorescence polarization experiments, the NS3/4A protease domain was 
purified as described previously in purification buffer (25mM HEPES, pH 7.5, 150mM 
NaCl, 20% glycerol, 4mM DTT) and subsequently concentrated to 200–400µM.  The 
concentrated stocks were then two-thirds serially diluted in 384-well plates (Corning) in 
reaction buffer using the Genesis Workstation (Tecan).  An equal volume of substrate 
buffer (25mM HEPES, pH 7.5, 0mM NaCl, 20% glycerol, 4mM DTT) containing 10nM 
of fluorescein-tagged substrate product (4A4B, 4B5A or 5A5B) was added to each well 
to make a final well volume of 60µL.  The final condition constituted 5nM fluorescein-
tagged cleavage products in 25mM HEPES (pH 7.5), 75mM NaCl, 20% glycerol and 
4mM DTT.  The plates were incubated at room temperature for two hours and five 
fluorescence polarization measurements were taken for each well using the Victor-3 plate 
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 reader (Perkins Elmer).  Five sets of binding data were collected for each substrate 
product and each trial was processed independently.  The average and standard deviations 
were then calculated from the results of these five trials.  Fluorescence polarization data 
(in milli-polarization units, mP) were fit to the Langmuir Equation, where ET is the total 
NS3/4A concentration, Kd is the equilibrium binding constant, b is the baseline 
fluorescence polarization and m is the fluorescence polarization maximum: 
 
mP = b + (m − b) ETET + Kd
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 RESULTS 
Structure determination of apo NS3/4A and product complexes 
The apo NS3/4A protease domain and host cell product complexes TRIF and 
MAVS all crystallized in the space group P212121 with one molecule in the asymmetric 
unit (Table 2.2).  For all structures, we utilized the highly soluble NS3/4A protease 
domain described previously, containing the essential residues of cofactor NS4A 
covalently linked at the N-terminus (12).  This NS3/4A construct also contains the 
inactivating mutation S139A, designed to further enhance protein stability by minimizing 
autoproteolysis during the crystallization process.  The partially inactivated variant still 
exhibits residual proteolytic activity, as observed for other serine proteases (27, 28), 
likely facilitated by the nucleophilic attack of water.  Thus the complete characterization 
of full-length substrate peptides was not possible and short peptides corresponding to the 
N-terminal cleavage products of authentic substrates were used for all crystallization 
trials.  Peptide products 4A4B, 4B5A, 5A5B and MAVS spanned P7–P1, while the TRIF 
sequence spanned P13–P1 with a tract of eight proline residues at the N-terminus (Table 
2.1).  The entire peptide sequence spanning P7–P1 could be modeled in each structure 
except for the TRIF complex, which revealed electron density for the residues spanning 
P6–P1 but not the polyproline tract. 
Tertiary structure analysis 
Structural analyses of the NS3/4A apo enzyme were carried out in conjunction 
with:  (i) the host cell product complexes TRIF and MAVS, (ii) the viral product 
complexes 4A4B, 4B5A and 5A5B (5), and (iii) the full-length NS3/4A structure (23), in 
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Table 2.2.  X-ray data collection and crystallographic refinement statistics. 
Dataset TRIF MAVS APO 
PDB ID 3RC4 3RC5 3RC6 
Modeled Ligand PSSTPC QEREVPC (unliganded) 
Resolution (Å) 1.50 (1.50–1.55) 1.60 (1.60–1.66) 1.30 (1.30–1.35) 
Space group P212121 P212121 P212121 
Molecules in AU† 1 1 1 
Cell dimensions:    
a (Å)= 53.9 54.1 54.8 
b (Å)= 58.1 58.2 58.6 
c (Å)= 61.3 61.3 60.9 
Completeness (%) 87.4 (93.1) 99.3 (99.1) 93.1 (97.1) 
Total reflections 136929 97504 190364 
Unique reflection 27770 26041 45595 
Average I/σ 13.5 (4.4) 18.8 (5.4) 14.8 (4.1) 
Redundancy 4.9 (4.7) 3.7 (3.7) 4.2 (4.0) 
Rsym (%)‡ 4.8 (30.1) 3.3 (19.3) 4.1 (29.3) 
RMSD∂ in:    
Bonds (Å) 0.009 0.009 0.009 
Angles (°) 1.28 1.26 1.29 
Rfactor (%)§ 18.7 17.3 16.2 
Rfree (%)§ 21.5 19.3 19.1 
† AU, asymmetric unit. 
‡ Rsym = Σ|I − <I>|/ΣI, where I = observed intensity, <I> = average intensity over symmetry 
equivalent. 
∂ RMSD, root mean square deviation. 
§ Rwork = Σ||Fo| − |Fc||/Σ|Fo|.  Rfree was calculated from 5% of reflections, chosen randomly, which 
were omitted from the refinement process. 
( ) Denotes statistics for the highest resolution shell. 
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 which the C-terminus represents the post-cleavage product 3-4A.  The seven structures 
constitute a total of twelve NS3/4A protease monomers, which all adopt the same 
chymotrypsin-like tertiary fold defined by the labeling-scheme for trypsin (29).  The N-
terminal distorted β-barrel subdomain contains two α-helices (α0 and α1) and seven β-
strands (A0–F1), while the C-terminal β-barrel subdomain comprises of two α-helices 
(α2 and α3) and six β-strands (A2–F2).  The cofactor NS4A contributes a single β-strand 
to the N-terminal distorted β-barrel, which is essential for efficient catalytic function (4).  
The catalytic triad is located in the cleft between these subdomains, with the N-terminal 
β-barrel contributing residues H57 and D81 and the C-terminal β-barrel contributing the 
nucleophilic S139.  The active site residues in all crystal structures share similar 
architecture, defined by the catalytic triad residues (S139A, H57, D81) and backbone 
nitrogens of the oxyanion hole (G137, S138, S139A). 
Certain global differences are observed between these structures when 
superpositions are performed.  Double-difference plots were therefore generated between 
each co-complex and the apo enzyme to determine the most invariant regions (Figure 
2.1).  Product 3-4A varied most extensively from the apo state, which likely reflects 
differences in genotype, protein size and crystal packing of the full-length construct.  The 
remaining product complexes derive from the same NS3/4A protease domain construct, 
and in general, vary less extensively from the apo enzyme.  Notably, the host cell product 
complexes are most similar to the apo enzyme, while viral product complexes 4A4B, 
4B5A and 5A5B vary more extensively.  Taken together, these findings suggest that 
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Figure 2.1:  Double-difference plots of product complexes.  Double-difference plots 
were computed for viral and host-cell product complexes relative to the apo enzyme 
structure.  NS3 protease residues are numbered according to the conventional system, 
whereas negative numbers indicate residues of the cofactor NS4A.  Red and blue contour 
lines represent positive differences of 1.0Å and 0.5Å, respectively, while black and green 
lines represent negative differences of the same magnitudes.
52
53
 structural differences likely reflect the inherent flexibility in certain regions of the 
protease. 
The set of double difference plots were further analyzed and the most invariant 
regions of the protease were determined to contain residues 32–36, 42–47, 50–54, 84–86, 
and 140–143 (Figure 2.1).  Product complexes 4A4B, 4B5A, 5A5B, TRIF and MAVS 
consist of ten protease molecules, which were subsequently superposed onto the apo 
enzyme using the Cα atoms of the structurally invariant residues.  The Cα average root 
mean square (RMS) deviation was calculated for each residue and the seven most 
variable regions of the protease were determined to be (Figure 2.2A):  (i) the linker 
connecting cofactor 4A at the N-terminus, (ii) the loop containing residues 65–70, (iii) 
the zinc-binding site containing residues 95–105, (iv) the 310 helix region spanning 
residues 128–136, (v) the zinc-binding site containing residues 145–148, (vi) the active 
site anti-parallel β-sheet containing residues 156–168, and (vii) the C-terminal α3 helix.  
These regions are solvent-exposed and likely influenced by both crystal packing effects 
and inherent flexibility. 
Extensive structural differences are observed near the active site as indicated by 
large RMS deviations for residues 156–168.  These differences are most pronounced for 
the β-strands E2 and F2, which form the anti-parallel β-sheet constituting the majority of 
the active site.  This region is least variable near the catalytic triad, while the average 
RMS deviations increase significantly toward the loop connecting these β-strands 
(Figure 2.2B).  Though the architecture of the protease catalytic triad is conserved, these 
observations suggest a potential dynamic interaction between the anti-parallel β-sheet of 
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Figure 2.2:  Average RMS deviations of product complexes.  All protease molecules 
from product complexes 4A4B, 4B5A, 5A5B, TRIF and MAVS were superposed onto 
the apo enzyme structure using the most invariant core residues 32–36, 42–47, 50–54, 
84–86 and 140–143.  (A) The average Cα RMS deviations were plotted versus residue 
number and (B) mapped onto a representative protease molecule with the most variable 
regions depicted in red and the most invariant regions depicted in blue.  The seven most 
variable regions of the protease are labeled in both panels.
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 the protease active site and substrate products.  Further studies are necessary to probe the 
nature and extent of such dynamic interplay.  Nevertheless, though the Cα atoms of 
active site residues shift relative to the protease core, these residues superpose well onto 
the APO enzyme with a RMS deviation range of 0.3–0.5Å.  Moreover, the residue side 
chains adopt similar rotamer conformations and interact with the same surrounding 
residues, suggesting that potential flexibility in the protease active site would not disrupt 
its tertiary structure.   
Analysis of viral product binding 
Fluorescence polarization experiments reveal that the viral products bind with 
different affinities to the protease, with the Kd for 4B5A over 10-fold weaker than those 
values for 4A4B and 5A5B (Figure 2.3).  Crystal structures reveal that these viral 
products bind in a conserved manner, forming an anti-parallel β-sheet with protease 
residues 154–160 and burying 500–600Å2 of solvent accessible surface area (30).  The 
peptide product backbone torsion angles are very similar, with positions P1–P4 being the 
most similar and residues P5–P7 deviating progressively toward the C-terminus.  A 
constrained P2 φ torsion angle of about –60° is observed in product complexes 3-4A, 
4A4B and 5A5B.  Interestingly, these P2 residues could sterically tolerate the substitution 
of proline, which is found at the P2 position in substrates 4B5A, TRIF and MAVS.  The 
ability of the P2 residue to adopt this constrained backbone torsion is a likely determinant 
in recognition process, allowing for the proper positioning of the P1 cysteine for catalysis 
in the active site.   
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Figure 2.3:  Fluorescence polarization of viral product binding.  Fluorescence 
polarization binding experiments were conducted with inactive S139A protease (circles) 
and the S139A/K136A variant (triangles) with fluorescein-tagged peptide products (A) 
4A4B, (B) 4B5A and (C) 5A5B.  For all conditions, trace amounts of peptide were 
incubated for two hours with increasing concentrations of NS3/4A protease in 25mM 
HEPES (pH 7.2), 75mM potassium chloride, 20% glycerol, 0.5µM zinc chloride and 
4mM DTT.  The panels depict a single representative trial, though each experiment was 
repeated five times.  (D) Data for each trial were processed independently by least-
squares regression fitting with the Langmuir Equation and the average and standard 
deviation of equilibrium dissociation constants (Kd) were calculated from the five repeats.
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 There are many conserved features in viral product binding, involving both 
backbone and side chain interactions (Figure 2.4).  For example, eight hydrogen bonds 
between backbone amide and carbonyl groups are completely conserved in the product 
complexes, involving protease residues G137, S138, S139A, R155, A157 and S159.  
S159 (C159 in product complex 3-4A) and A157 each contribute two hydrogen bonds 
with bound products at positions P5 and P3, respectively.  The P1 residue, cysteine in all 
substrates but 3-4A, interacts favorably with the π-system of electrons of F154.  All P1 
terminal carboxyl groups sit in the oxyanion hole, hydrogen bonding with the Nε nitrogen 
of H57 and the amide nitrogens of residues 137–139.  Though the coordinates of the P1 
terminal oxygen atom are not included in the full-length NS3/4A structure, geometric 
restraints would position it similarly to the other peptide products.  Thus the same set of 
protease residues contacts all peptide sequences, although the precise nature of these 
interactions varies depending on the particular residue involved in each contact.  
Despite these similarities, there are also unique features that likely underlie the 
particular specificity of NS3/4A for each substrate (Figure 2.4).  For example, the four 
acidic residues in product 4A4B lead to a highly charged peptide in solution.  In the 
bound state, however, the atomic geometry suggests that the P5 glutamate is protonated 
and hydrogen bonding with the carboxyl group of the P3 glutamate, which itself forms an 
ionic interaction with the terminal nitrogen of K136.  In fact, K136 interacts differently 
with all four viral products, forming: (i) a hydrogen bond with the P2 carbonyl oxygen of 
3-4A, (ii) a salt bridge with the P3 glutamate of 4A4B, and (iii) an extended 
conformation that does not interact considerably in product complexes 4B5A and 5A5B.  
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Figure 2.4:  Stereo view of viral product binding to NS3/4A protease.  N-terminal 
cleavage products (A) 3-4A, (B) 4A4B, (C) 4B5A, and (D) 5A5B are shown bound to the 
protease active site with the electrostatic interactions of backbone and sidechain atoms 
depicted in black and red, respectively.
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 Fluorescence polarization data confirms a more significant loss in binding affinity of 
product 4A4B for the K136A protease variant compared to products 4B5A and 5A5B 
(Figure 2.3).  Thus the affinity of a substrate product likely arises from the side chain 
interactions unique to that particular product. 
NMR solution studies of product 4A4B binding 
The NS3/4A protease active site is located on the surface of the protein and thus 
highly solvent-exposed.  The analysis of viral and host cell product binding is therefore 
complicated by the proximity of symmetry-related molecules within the crystal lattice.  
To investigate the possibility of crystal packing effects confounding structural 
observations, we carried out NMR HSQC titration experiments using peptide product 
4A4B spanning P7–P1 (Figure 2.5A).  HSQC chemical shift perturbations upon product 
titration are consistent with the molecular interactions observed in the crystal complex.  
The normalized chemical shift perturbations for each protease residue were compared to 
the buried surface area calculated directly from product complex 4A4B (Figure 2.5B).  
These data indicate that the same set of protease residues with large chemical shift 
perturbations are also observed to interact extensively with product 4A4B in the crystal 
structure.  The NMR solution studies recapitulate our structural observations and suggest 
that our crystal structure analyses are indeed representative of the interactions occurring 
in solution. 
Analysis of host cell product complexes TRIF and MAVS 
Active site superpositions (residues 137–139; 154–160) reveal that TRIF and 
MAVS peptide products both bind to the protease active site in a conserved three-
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Figure 2.5:  NS3/4A H1, N15 NMR HSQC titration data.  (A) NMR spectra reveal 
N15 labeled NS3/4A chemical shift perturbations upon titration of increasing 
concentrations of substrate 4A4B product peptide.  Cross-peaks are colored according to 
the concentration of peptide product 4A4B, ranging from 0mM (blue) to 2.5mM (red).  
For clarity, the titration data for the highest peptide concentration (2.5mM) are only 
depicted in the insets.  (B) The apo NS3/4A crystal structure was colored according to the 
chemical shift changes between the apo enzyme state and 2.5mM product 4A4B.  
Protease residues undergoing chemical shifts are colored by a spectrum ranging from 
pink (small shifts) to red (large shifts).  All unassigned residues are shown in white.
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 dimensional shape (Figure 2.6).  Both substrate products form anti-parallel β-sheets with 
protease residues 154–160.  There is no clear electron density in the TRIF complex for 
the proline residues spanning P13–P7.  Nevertheless, the residues from P6–P1 overlap 
closely with the corresponding residues in the MAVS complex.  The P1 cysteine residues 
of both substrate products interact with the aromatic ring of F154.  Eight hydrogen bonds 
are observed in both structures, involving the amide nitrogens or carboxyl oxygens of 
residues G137, S138, S139A, R155, A157 and S159.  A157 and S159 each contribute 
two hydrogen bonds with the P3 and P5 residues, respectively.  In both structures, the 
carbonyl groups at position P1 interact with the protease oxyanion hole, defined by the 
backbone amide nitrogens of residues 137–139.  Thus, the post-cleavage products of the 
cellular substrates TRIF and MAVS bind to the protease active site in a conserved 
manner despite their large variations in primary sequence.  
There are also many differences in the binding of TRIF and MAVS involving 
mainly sidechain interactions with the protease (Figure 2.6).  For example, MAVS 
interacts closely with the protease electrostatic network formed by residues D81, R155, 
D168 and R123.  The P4 glutamate of MAVS interacts with R155 and R123 in this 
network, while the P6 glutamate forms a salt bridge with R123.  The TRIF peptide 
product, however, lacks such extended residues on this surface of the molecule, and the 
electrostatic network is notably absent with the participating residues adopting 
conformations observed in the apo structure.  Previous studies demonstrate that a large 
fraction of full-length TRIF exists as polyproline II helices, and that the interaction of 
NS3/4A with a polyproline II helix facilitates TRIF cleavage (11).  The absence of clear 
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Figure 2.6:  Stereo view of host cell product binding to NS3/4A protease.  (A) The 
apo enzyme structure and N-terminal cleavage products (B) TRIF and (C) MAVS are 
shown bound to the protease active site with the electrostatic interactions of backbone 
and sidechain atoms depicted in black and red, respectively.
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 electron density for the proline residues suggests that full-length TRIF may be necessary 
to stabilize the polyproline tract in a conformation capable of specific interaction with 
NS3/4A. 
Comparison of host cell and viral product binding 
Host cell product binding was analyzed on a broader basis by comparison with the 
binding of viral substrates, previously reported by our group (5).  Both viral (3-4A, 
4A4B, 4B5A, 5A5B) and host cell (TRIF, MAVS) substrate products bind to the protease 
active site in a conserved three-dimensional shape.  The peptide backbone torsional 
angles are very similar, being most conserved at position P1 and deviating slightly toward 
position P6.  All peptide products adopt constrained P2 Ψ torsion angles, even those 
containing non-proline residues at this site.  However, vdW analyses of substrate 
products indicate large variations in sidechain interactions with the protease.  All of the 
NS3/4A substrates contain either cysteine or threonine at position P1, while five of the 
six contain an acid at position P6.  The P1 and P6 substrate residues each contribute the 
same amount of vdW energies in all product complexes (Figure 2.7).  The amino acid 
makeup of viral cleavage sequences is much more diverse at positions P5–P2, and in 
general, the vdW energies at each position correlate with amino acid size.  For example, 
the P4 glutamates in substrates 3-4A and MAVS, and to a lesser extent the P4 methionine 
in substrate 4A4B, are associated with larger vdW energies relative to the substrates with 
smaller P4 residues.  Likewise, the larger glutamate residues at both P3 and P2 of 
substrate 4A4B also correlate with greater contact energies compared to the other 
substrates, which contain smaller amino acids at these positions. 
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Figure 2.7:  vdW energies of substrate product binding.  The vdW binding energies 
by residue for each NS3/4A cleavage products (3-4A, 4A4B, 4B5A, 5A5B, TRIF and 
MAVS) are graphically depicted with their primary sequences tabulated.
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 Though similar in shape, protease substrate binding can be further categorized 
into two groups:  (i) product complexes 3-4A, 4A4B, 5A5B and MAVS bind with an 
intact electrostatic network involving residues D81, R155, D168 and R123, while (ii) 
product complexes 4B5A and TRIF bind without this network such that R155, D168 and 
R123 maintain conformations observed in the apo enzyme.  Notably, the 4B5A and TRIF 
cleavage sites contain fewer charged residues compared to the other substrates, which 
may underlie their inability to form the electrostatic network.   Binding studies 
demonstrate that both 4B5A and TRIF have relatively weaker affinities for NS3/4A 
compared to the other substrates (11, 31).  However, most biochemical studies have been 
conducted on small peptides corresponding to the immediate cleavage sequences of TRIF 
and 4B5A.  Indeed, kinetic studies revealed that full-length TRIF is processed more 
efficiently than peptides corresponding to the cleavage sequence (11).  Additional 
molecular interactions by the full-length proteins or by adaptor proteins in the authentic 
cellular environment may better facilitate substrate binding.  Nevertheless, the current 
structural analyses suggest that NS3/4A substrates vary in specificity by their ability to 
form and stabilize the protease electrostatic network; the sequence specificity is 
particularly influenced by amino acid variation at positions P6, P4 and P2.  
Analysis using the viral substrate envelope 
The binding of NS3/4A cellular substrates was analyzed in terms of the viral 
substrate envelope (Figure 2.8), which was previously defined as the vdW volume shared 
by any three of four viral products (5).  This shape could not be predicted by the primary 
sequences alone and highlights the conserved mode of viral substrate recognition despite 
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Figure 2.8:  Host-cell product binding and the NS3/4A substrate envelope.  (A) The 
NS3/4A substrate envelope is calculated from the consensus van der Waals volume 
shared by any three of the four viral products.  (B) The TRIF cleavage product is 
confined within the substrate envelope, (C) while MAVS is mostly located within the 
substrate envelope except for the sidechain atoms spanning P6–P4.
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 their high sequence diversity.  The backbone chains of both TRIF and MAVS fit entirely 
within the substrate envelope, as well as the sidechains of TRIF spanning P5–P1.  The 
sidechains of MAVS are also mostly confined within the substrate envelope, except for 
the longer side chains of the P6 glutamate, P5 arginine and P4 glutamate.  The carboxylic 
acids of these glutamate residues interact extensively with the protease electrostatic 
network, while the P5 arginine packs against loop residues 159–162.  As these 
interactions occur outside the viral substrate envelope, we speculate that mutations that 
disrupt the electrostatic network, such as R155K and D168A, would preferentially reduce 
the proteolytic processing of MAVS compared to TRIF. 
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 DISCUSSION 
The recognition and proteolysis of the viral polyprotein and host cell adaptor 
proteins by NS3/4A protease play an integral role in the ability of HCV to replicate and 
evade the innate immune response to viral infection (7, 10).  In this study, crystal 
structures of the NS3/4A protease domain reveal that viral and host cell products bind to 
the protease active site in a similar three-dimensional shape, defined by the viral substrate 
envelope reported previously.  The MAVS product complex reveals the formation of an 
extensive electrostatic network involving protease residues D81, R155, D168 and R123, 
which also form in viral product complexes 3-4A, 4A4B and 5A5B.  No such networks 
form in the TRIF and 4B5A complexes, and residues in this region of the protease adopt 
the same conformations observed in the apo state.  The absence or presence of 
electrostatic networks also correlate with the affinities of product binding, with the Kd of 
4B5A being 10-fold weaker compared to products 4A4B and 5A5B.  The greater 
catalytic efficacies of NS3/4A for substrates 4A4B and 5A5B relative to 4B5A (31) may 
also derive from the formation of electrostatic networks.  However, short peptide may 
only partially mimic how the viral cleavage sequences are processed along the viral 
polyprotein in the natural cellular environment.  Additional molecular features may 
further modulate the binding of TRIF and 4B5A, perhaps facilitated by the proline-rich 
regions contained in both proteins (11).  Thus, the specificity of substrate processing by 
NS3/4A protease seems to arise from at least two distinct molecular interaction patterns, 
which likely influence the order and kinetics of polyprotein processing during the HCV 
lifecycle.  
76
 In fact, these structural observations can be further linked to the known biology of 
NS3/4A processing during viral replication.  Previous NS3-mediated cleavage assays of 
HCV polyprotein substrates revealed that NS4A is essential for the trans cleavage of 
junction 4B5A, but not required for the processing of junctions 4A4B and 5A5B (3, 4).  
Our structural analyses provide further insight into the molecular interactions underlying 
these previous findings.  The NS4A cofactor likely stabilizes the tertiary protease fold 
required for the binding of NS3/4A substrates, and the binding of substrate 4B5A may 
absolutely depend on this particular protease conformation.  Substrates 4A4B and 5A5B, 
however, may be able to induce these conformational changes through charge 
interactions, even in the absence of cofactor NS4A.  Thus our findings support the 
previous published data for NS3 HCV polyprotein processing, and future research is 
warranted to better ascertain the dynamic mechanisms of substrate recognition. 
The ability for HCV to establish chronic human infections is highly dependent on 
the viruses ability to effectively replicate while simultaneously evading the host cell 
immune response.  The virally encoded NS3/4A protein plays an integral role in this 
process by mediating the cleavage of essential viral proteins and antiviral host cell 
adaptors.  NS3/4A protease is thus a prime therapeutic target and great efforts have been 
devoted in the development of protease inhibitors, which have demonstrated efficacy in 
late phases of human clinical trials.  Nevertheless, the high rate and error-prone nature of 
HCV replication has led to the emergence of drug resistance against the most promising 
protease inhibitors to date, such as boceprevir, telaprevir and danoprevir (32-37).  
Inhibitor potency often derives from molecular interactions that are not essential for 
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 substrate recognition and cleavage.  Mutations in these regions of the protease can 
selectively prevent drug binding while still allowing for the recognition and cleavage of 
viral and host cell substrates.  Thus identification of the protease residues that are 
important for substrate binding is crucial and will ultimately facilitate the design of drugs 
that target these particular residues.  A more detailed understanding of the mechanisms 
underlying viral and host cell substrate recognition is therefore essential in facilitating a 
more rationale approach to the design of more robust NS3/4A protease inhibitors. 
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CHAPTER III 
DRUG RESISTANCE AGAINST HCV NS3/4A PROTEASE INHIBITORS:            
THE BALANCE OF SUBSTRATE RECOGNITION AND INHIBITOR BINDING 
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 ABSTRACT 
Hepatitis C virus infects an estimated 180 million people worldwide, prompting 
enormous efforts to develop inhibitors targeting the essential NS3/4A protease.  
Resistance against the most promising protease inhibitors, telaprevir, boceprevir and 
danoprevir, has emerged in clinical trials.  In this study, crystal structures of the NS3/4A 
protease domain reveal that viral substrates bind to the protease active site in a conserved 
manner defining a consensus volume, or substrate envelope.  Mutations that confer the 
greatest resistance occur where inhibitors protrude from the substrate envelope, as these 
changes selectively weaken inhibitor binding without compromising the binding of 
substrates.  These findings suggest a general model for predicting the susceptibility of 
protease inhibitors to resistance: drugs designed to fit within the substrate envelope will 
be less susceptible to resistance, as mutations affecting inhibitor binding would 
simultaneously interfere with the recognition of viral substrates. 
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 INTRODUCTION 
Drug resistance impedes the treatment of quickly evolving diseases.  Hepatitis C 
virus (HCV), a genetically diverse Flavivirus, infects an estimated 180 million people 
worldwide (1).  The viral RNA genome encodes a single polyprotein that is subsequently 
cleaved by host cell and viral proteases into structural (C, E1, E2, p7) and non-structural 
(NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins (2).  The viral RNA-dependent RNA 
polymerase, NS5B, is inherently inaccurate and misincorporation of bases accounts for a 
very high mutation rate (3).  While some mutations are neutral, others will alter the 
viability of the virus and propagate with varying efficiencies in each patient.  Thus HCV 
infected individuals will develop a heterogeneous population of virus variants known as 
quasispecies (4).  As patients begin treatment, the selective pressures of antiviral drugs 
will favor drug resistant variants (5).  Therefore, an inhibitor must not only recognize one 
protein variant, but an ensemble of related enzymes.  A detailed understanding of the 
atomic mechanisms of resistance is therefore essential to effectively combat drug 
resistance against HCV antivirals. 
The essential HCV NS3/4A protease is an attractive therapeutic target responsible 
for cleaving at least four sites along the viral polyprotein.  These sites share little 
sequence homology except for an acid at position P6, cysteine or threonine at P1, and 
serine or alanine at P1' (Table 3.1).  The first cleavage occurs at the 3-4A junction in cis, 
while the remaining substrates are processed in trans.  The NS3/4A protease also cleaves 
the human cellular targets TRIF and MAVS, which has been shown to confound the 
innate immune response to viral infection (6-8).  Early drug design efforts were hampered 
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Table 3.1.  Genotype 1a NS3/4A substrate cleavage sequences 
Substrate P6 P5 P4 P3 P2 P1 P1' P2' P3' P4' 
3-4A D L E V V T S T W V 
4A4B D E M E E C S Q H L 
4B5A E C T T P C S G S W 
5A5B E D V V C C S M S Y 
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 by the relatively shallow, featureless architecture of the protease active site.  The eventual 
observation of N-terminal product inhibition served as a stepping-stone for the discovery 
of more potent peptidomimetic inhibitors (9, 10).  Over the past decade, pharmaceutical 
companies have further developed these lead compounds.  Many structure-activity-
relationship (SAR) studies have been performed to evaluate the effect of different 
functional moieties on protease inhibition at positions P4–P1' (11-17).  Crystal structures 
have been determined of NS3/4A protease bound to a variety of inhibitors as well as of 
several drug resistant protease variants, such as R155K and V36M (18, 19).  These data 
elucidate the molecular interactions of NS3/4A with inhibitors and the effect of specific 
drug resistance mutations on binding.  These efforts, conducted in parallel by several 
pharmaceutical companies, led to the discovery of many protease inhibitors.  Proof-of-
concept for the successful clinical activity of this drug class was first demonstrated by the 
macrocyclic inhibitor ciluprevir (Boehringer Ingelheim) (20, 21), which was later 
dropped from clinical trials due to cardiotoxicity (22).  Many other NS3/4A protease 
inhibitors continue to advance in clinical trials, and telaprevir (Vertex) and boceprevir 
(Merck) are currently approved for clinical use in humans (Figure 3.1A). 
Despite these successes, the rapid acquisition of drug resistance has limited the 
efficacy of the most potent NS3/4A protease inhibitors in both replicon studies and 
human clinical trials (Figure 3.1B; Table 3.2).  In this study, we show that mutations 
conferring the most severe resistance occur where the protease extensively contacts the 
inhibitors but not the natural viral substrates.  Four crystal structures of the NS3/4A 
protease domain in complex with the N-terminal products of viral substrates reveal a 
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Figure 3.1:  NS3/4A protease inhibitors and sites of drug resistance.  (A) The leading 
protease inhibitors in development mimic the N-terminal side of the viral substrates.  (B) 
The majority of reported drug resistance mutations cluster around the protease active site 
with the catalytic triad depicted in yellow.
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 Table 3.2. Reported sites of drug resistance mutations 
Res. Mutation Drug 
V36 A, M, L, G Boceprevir, telaprevir 
Q41 R Boceprevir, danoprevir 
F43 S, C, V, I Boceprevir, telaprevir, danoprevir, TMC435 
V55 A Boceprevir 
T54 A, S Boceprevir, telaprevir 
Q80 K, R, H, G, L TMC435 
S138 T Danoprevir, TMC435† 
R155 K, T, I, M, G, L, S, Q Boceprevir, telaprevir, danoprevir, ciluprevir, TMC435 
A156 V, T, S, I, G Boceprevir, telaprevir, danoprevir, ciluprevir, TMC435 
V158 I Boceprevir 
D168 A, V, E, G, N, T, Y, H, I Danoprevir, ciluprevir, TMC435 
V170 A Boceprevir, telaprevir 
M175 L Boceprevir 
†-TMC435 displays reduced activity against S138T, but the mutation was not observed in selection 
experiments. 
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 conserved mode of substrate binding, with the consensus volume defining the substrate 
envelope.  The protease inhibitors danoprevir (3M5L), TMC435 (3KEE) (23) and 
boceprevir (2OC8) (24) protrude extensively from the substrate envelope in regions that 
correlate with known sites of resistance mutations.  Most notably, the P2 moieties of all 
three drugs protrude to contact A156 and R155, which mutate to confer high-level 
resistance against nearly all drugs reported in the literature (25-30).  These findings 
suggest that drug resistance results from a change in molecular recognition and imply that 
drugs designed to fit within the substrate envelope will be less susceptible to resistance, 
as mutations altering inhibitor binding will simultaneously interfere with the binding of 
substrates.  
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 MATERIALS AND METHODS 
Mutagenesis and gene information 
The HCV genotype 1a NS3/4A protease gene described in a Bristol-Meyers 
Squibb patent (31) was synthesized by GenScript and cloned into the pET28a expression 
vector (Novagen).  The gene encodes a highly soluble form of the NS3/4A protease 
domain as a single-chain, with 11 core amino acids of NS4A located at the N-terminus.  
The inactive S139A protease variant was subsequently constructed using the QuikChange 
Site-Directed Mutagenesis Kit from Stratagene and sequenced by Davis Sequencing for 
confirmation. 
Viral peptide product purchase and storage 
Thirty milligrams of each substrate peptide and the corresponding N-terminal 
cleavage product (4A4B, 4B5A, 5A5B) were purchased from 21st Century Biochemicals 
(Marlboro, MA) at 95% purity.  The purity was determined by HPLC and mass 
spectrometry profiles as provided by the company.  The substrates were synthesized as 
12-mers, extending the substrate sequence by an additional amino acid on each side of 
the minimal cleavage sequence of the HCV polyprotein.  Peptide products were 
synthesized at 7-mers spanning P7–P1.  The N-termini of all peptides were acetylated, 
while the C-termini of substrate peptides were blocked with amide groups.  All peptides 
were stored as solids at −20ºC and dissolved in DMF to a final concentration of 50–
100mM for crystallization trials. 
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 Protein expression and purification 
NS3/4A expression and purification were carried out as described previously (31, 
32).  Briefly, transformed BL21(DE3) E. coli cells were grown at 37ºC to an OD of 0.8 
and subsequently induced with the addition of 1mM IPTG.  Cells were harvested after 5 
hours of expression, pelleted and frozen at −80ºC for storage.  Cell pellets were thawed, 
resuspended in 5mL/g of Resuspension Buffer (50mM phosphate buffer at pH 7.5, 
500mM NaCl, 10% glycerol, 2mM β-ME) and lysed with a cell disruptor.  The soluble 
fraction was retained, applied to a nickel column (Qiagen), washed with Resuspension 
Buffer, and eluted with Resuspension Buffer supplemented with 200mM imidazole.  The 
eluant was dialyzed overnight (MWCO 10kD) to remove the imidazole and the his-tag 
was simultaneously removed with thrombin treatment.  The nickel-purified protein was 
then flash-frozen and stored at −80ºC for up to six months. 
Protein crystallization 
The NS3/4A protease construct described previously (31) was expressed and 
purified as reported previously (31, 32), detailed in the supporting information.  Purified 
protein was concentrated to ~3mg/mL and loaded on a HiLoad Superdex75 16/60 column 
equilibrated with 25mM MES at pH 6.5, 500mM NaCl, 10% glycerol, 30µM zinc 
chloride, and 2mM DTT.  The protease fractions were pooled and concentrated to 20–
25mg/mL with an Amicon Ultra-15 device (MWCO 10kD; Millipore).  The concentrated 
samples were then incubated at 4°C for one hour with 2–20 molar excess of viral 
substrate 4A4B, peptide products 4B5A or 5A5B, or danoprevir.  Information about the 
synthesis of viral peptides and danoprevir is provided in the supporting information.  
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 Diffraction-quality crystals were obtained overnight for all ligands by mixing equal 
volume of concentrated protein solution with precipitant solution (20–26% PEG-3350, 
0.1M sodium MES buffer at pH 6.5, and 4% ammonium sulfate) in 24-well VDX 
hanging drop trays. 
Data collection and structure solution  
Crystals were flash-frozen in liquid nitrogen and mounted under constant 
cryostream.  X-ray diffraction data were collected at Advanced Photon Source BioCARS 
14-IDB, 14-BMC, and LS-CAT 21-ID-F.  Diffraction intensities of the complexes were 
indexed, integrated and scaled using the programs HKL2000 (33) and XDS (34). 5% of 
the data was used to calculate R-free (35).  All structure solutions were generated using 
isomorphous molecular replacement with PHASER (36) or AMORE.  The NS3/4A 
protease domain (PDB code 2A4G) (37) was used for molecular replacement in solving 
the product 4A4B structure, and this structure was subsequently used for solving the 
other complexes.  In all cases, initial refinement was carried out in the absence of 
modeled ligand, which was subsequently built in.  Phases were improved using 
ARP/wARP (38).  Iterative rounds of TLS and restrained refinement with CCP4 (39) and 
graphical model building with COOT (40) until R-value convergence.  All structures 
were evaluated with MolProbity (41) before deposition in the protein data bank.  
Structural analysis 
Double-difference plots (42) were used to determine the structurally invariant 
regions of the protease, consisting of residues 32–36, 42–47, 50–54, 84–86 and 140–143.  
Structures were superimposed with PyMOL (43) using the Cα atoms of these residues for 
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 all protease molecules from the solved structures (nine total).  The B chain of product 
complex 4A4B was used as the reference structure in all alignments.  Fit of individual 
inhibitors into the substrate envelope was quantified by mapping the substrate envelope 
and the van der Waals (vdW) volume of each inhibitor on a three-dimensional grid with 
spacing of 0.5Å.  Vout for each drug moiety was computed by counting the grid cells, 
which were occupied by any inhibitor atom of that site but not the substrate envelope, and 
multiplied by the grid cell size, 0.125Å3 (44, 45). 
Substrate envelope and inhibitor analyses 
NS3/4A substrate envelope was computed using product complexes 4A4B (B 
chain), 4B5A (D chain) and 5A5B (A chain).  In structures with multiple protease 
molecules in the asymmetric unit, the one containing the most ordered peptide product 
was used for the alignment.  The protease domain of the full-length NS3/4A structure (A 
chain; PDB code 1CU1) (46), including the C-terminal six amino acids, was included as a 
product complex 3-4A.  All active site alignments were performed in PyMOL using Cα 
atoms of protease residues 137–139 and 154–160.  After superposition, gaussian object 
maps were generated in PyMOL for each cleavage product.  Four consensus gaussian 
maps were then calculated, representing the intersecting volume of a group of three 
object maps.  Finally, the summation of these four consensus maps was generated to 
construct the substrate envelope, depicting the vdW volume shared by any three of the 
four products.  The previously determined boceprevir complex (PDB code 2OC8) (24) 
and TMC435 complex (PDB code 3KEE) (23) were used in this study (47). 
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 RESULTS 
Synthesis of danoprevir 
We synthesized the macrocyclic inhibitor danoprevir using the convergent 
reaction sequence described in the Supplemental Experimental Procedures.  Briefly, the 
P2 and P1–P1' fragments were preassembled and the macrocyclic drug compound was 
generated by a four-step reaction sequence, including P2–P3 amide coupling, ester 
hydrolysis, coupling with the P1–P1' fragment, and ring-closing metathesis.  The P2–P3 
fragment was assembled by coupling the commercially available Boc-protected amino 
acid (S)-2-(tert-butoxycarbonylamino)non-8-enoic acid (Acme Biosciences, Inc., CA) 
with the preassembled P2 fragment, (3R,5S)-5-(methoxycarbonyl)pyrrolidin-3-yl 4-
fluoroisoindoline-2-carboxylate (48), using HATU/DIPEA conditions.  Hydrolysis of the 
P2–P3 methyl ester with LiOH.H2O in a mixture of THF-MeOH-H2O followed by 
coupling of the resulting acid under HATU/DIPEA conditions with the preassembled P1–
P1' fragment, (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropane-
carboxamide (49), provided the bis-olefin precursor for ring-closing metathesis.  
Cyclization of the bis-olefin intermediate was accomplished using a highly efficient ring-
closing metathesis catalyst Zhan 1B and provided the protease inhibitor danoprevir. 
Structure determination of inhibitor and substrate complexes 
Although NS3/4A cleaves the 3011-residue viral polyprotein at four specific sites 
in vivo, we focused on the local interactions of the protease domain with short peptide 
sequences corresponding to the immediate cleavage sites.  All structural studies were 
carried out with the highly soluble, single-chain construct of the NS3/4A protease domain 
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 described previously (31), which contains a fragment of the essential cofactor NS4A 
covalently linked at the N-terminus by a flexible linker.  A similar protease construct was 
shown to retain comparable catalytic activity to the authentic protein complex (50).  
Crystallization trials were initially carried out using the inactive (S139A) protease variant 
in complex with substrate peptides spanning P7–P5'.  The 4A4B substrate complex 
revealed cleavage of the scissile bond and no ordered regions for the C-terminal fragment 
of the substrate.  Similar observations were previously described for two other serine 
proteases where catalytic activity was observed, presumably facilitated by water, despite 
alanine substitutions of the catalytic serine (51, 52).  Thus all subsequent crystallization 
trials with the NS3/4A protease were performed using N-terminal cleavage products of 
the viral substrates spanning P7–P1. 
NS3/4A crystal structures in complex with danoprevir and peptide products 
4A4B, 4B5A and 5A5B were determined and refined at 1.25Å, 1.70Å, 1.90Å and 1.60Å 
resolution, respectively (Table 3.3).  The complexes crystallized in the space groups 
P212121 and P21 with between one and four molecules in the asymmetric unit.  The 
average B factors range from 16.8–29.7Å2, and there are no outliers in the Ramachandran 
plots.  These structures represent the highest resolution crystal structures of NS3/4A 
protease reported to date. 
Overall structure analysis 
The NS3/4A protease domain adopts a tertiary fold characteristic of serine 
proteases of the chymotrypsin family (53, 54).  A total of nine protease molecules were 
modeled in the four crystal structures solved in this study with an overall root-mean-
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 Table 3.3.  X-ray data collection and crystallographic refinement statistics. 
Dataset Product 4A4B Product 4B5A Product 5A5B Danoprevir 
PDB ID 3M5M 3M5N 3M5O 3M5L 
Modeled Ligand FDEMEEC SECTTPC TEDVVCC Danoprevir 
Resolution (Å) 1.70 1.90 1.60 1.25 
Space group P212121 P21 P21 P212121 
Molecules in AU§ 2 4 2 1 
Cell dimensions:     
a (Å)= 58.2 67.3 47.3 55.2 
b (Å)= 60.1 58.9 58.9 58.7 
c (Å)= 95.7 98.3 67.1 61.1 
β (°)= 90.0 101.0 99.2 90.0 
Completeness (%) 99.7 99.4 94.7 99.7 
Total reflections 278535 213010 150463 317137 
Unique reflection 37615 59622 45685 52645 
Average I/σ 10.2 12.4 17.4 20.7 
Redundancy 7.4 3.6 3.3 6.0 
Rsym (%)¶ 6.2 5.3 6.7 4.6 
RMSD† in:     
Bonds (Å) 0.009 0.009 0.009 0.009 
Angles (°) 1.25 1.53 1.26 1.48 
Rfactor (%)* 17.7 18.8 18.0 15.0 
Rfree (%)* 20.6 24.0 22.6 16.8 
§- AU, asymmetric unit. 
¶- Rsym = Σ|I − <I>|/ΣI, where I = observed intensity, <I> = average intensity over symmetry 
equivalent. 
†- RMSD, root mean square deviation. 
*- Rwork = Σ||Fo| − |Fc||/Σ|Fo|.  Rfree was calculated from 5% of reflections, chosen randomly, which 
were omitted from the refinement process. 
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 square deviation (RMSD) of 0.28Å.  The RMSDs reveal the five most variable regions of 
the protease to be (Figure 3.2):  (i) the linker connecting cofactor 4A at the N-terminus, 
(ii) the loop containing residues 65–70, (iii) the zinc-binding site containing residues 95–
105, (iv) the 310 helix region spanning residues 128–136, and (v) the active site anti-
parallel β-sheet containing residues 156–168.  These structural differences likely indicate 
inherent flexibility in the protease and do not appear to correlate with ligand type or 
active site occupancy. 
Analysis of product complexes 
Product complexes 4A4B, 4B5A and 5A5B were further analyzed with the C-
terminus of the full-length NS3/4A structure (1CU1), which contains the N-terminal 
cleavage product of viral substrate 3-4A (46).  All four products bind to the protease 
active site in a conserved manner (Figure 3.3), forming an anti-parallel β-sheet with 
residues 154–160 and burying 500–600Å2 of solvent accessible surface area as calculated 
by PISA (55).  The peptide backbone torsions are very similar, being most conserved at 
position P1 and deviating slightly toward position P4.  Eight hydrogen bonds between 
backbone amide and carbonyl groups are completely conserved, involving protease 
residues S159 (C159 in product 3-4A), A157, R155, S139A, S138, and G137.  S159 
(C159 in product 3-4A) and A157 each contribute two hydrogen bonds with the P5 and 
P3 peptide residues, respectively.  All P1 terminal carboxyl groups sit in the oxyanion 
hole, hydrogen bonding with the Nε atom of H57 and the amide nitrogens of residues 
137–139.  Although only product 4B5A contains a proline at P2, the other substrate 
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Figure 3.2:  Structural variations between protease molecules of solved crystal 
complexes.  (A) The Cα RMSDs of all nine protease molecules from the four crystal 
structures determined in this study are plotted as a function of residue number after 
superimposition using the core residues 33–37, 51–54, 81–86 and 140–144.  (B) The 
RMSD values were then used to color the NS3/4A structure with a rainbow gradient.  
Blue indicates structurally conserved regions of the protein, while red regions are the 
most variable from structure to structure.
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Figure 3.3:  Stereo view of cleavage product binding to NS3/4A protease.  N-terminal 
protease cleavage products (A) 3-4A, (B) 4A4B, (C) 4B5A and (D) 5A5B are depicted as 
they bind to the protease active site.  All conserved interactions are indicated by black 
dashes, while red lines depict interactions that are not present in all structures.  The 
electrostatic networks involving residues R123, D168, R155 and D81 are indicated by 
blue dashes.
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 sequences still adopt constrained P2 φ torsion angles.  Thus products bind similarly 
despite their high sequence diversity. 
The P1 and P6 residues are most conserved among the substrate sequences, as are 
most of their interactions with the protease.  The P1 side chains interact with the aromatic 
ring of F154.  In all structures but product complex 4B5A, K165 forms salt-bridges with 
the P6 acids, while residues R123, D168, R155, and the catalytic D81 form an ionic 
network along one surface of the bound products (Figure 3.3).  In complex 4B5A, R123 
interacts directly with the P6 acid, while D168 reorients and no longer contacts R155.  
Other molecular interactions in the product complexes are more diverse.  Notably, K136 
interacts differently with the cleavage products, forming:  (i) a hydrogen bond with the 
P2 backbone carbonyl oxygen of 3-4A, (ii) a salt-bridge with the P3 glutamate of product 
4A4B, and (iii) nonspecific vdW interactions with the P2 and P3 side chains of products 
4B5A and 5A5B.  Also, in product complex 4A4B, an intramolecular hydrogen bond 
forms between the P3 and P5 glutamate residues, while the unique P4 acid of product 3-
4A forms salt-bridges with the guanidinium groups of R123 and R155.  Thus distinct 
patterns of side chain interactions underlie the set of conserved features involved in 
NS3/4A cleavage product binding. 
The substrate envelope 
To further analyze the structural similarities of the four NS3/4A product 
complexes, the active sites were superposed on the Cα atoms of residues 137–139 and 
154–160, revealing that both the active site residues and substrate products spanning P6–
P1 align closely with an average Cα RMSD of 0.24Å and 0.35Å, respectively.  The 
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 consensus vdW volume shared by any three of the four cleavage products was then 
calculated to generate the NS3/4A substrate envelope (Figure 3.4A).  This shape could 
not be predicted by the primary sequences alone and highlights the conserved mode of 
viral substrate recognition despite their high sequence diversity.  
Analysis of inhibitor complexes  
Danoprevir, TMC435 and boceprevir are all peptidomimetic NS3/4A protease 
inhibitors.  Active site superpositions of these drug complexes reveal that the inhibitors 
interact with many of the same protease residues as the cleavage products.  Despite the 
P3–P1 cyclization of danoprevir and TMC435, the functional groups are positioned 
similarly in all three inhibitor complexes.  The P1 cysteine surrogates interact with the 
aromatic ring of F154, while the P2 and P3 moieties overlap closely.  Although TMC435 
does not contain a P4 substituent, the P4 tert-butyl groups of danoprevir and boceprevir 
also align closely.  In addition, the P1 and P3 backbone atoms of all inhibitors hydrogen 
bond with the carbonyl oxygens of R155 and A157, respectively.  These observations 
verify the peptidomimetic nature of these drugs and support their observed mechanism as 
competitive active site inhibitors. 
The largest variation between these three protease inhibitors occurs at P2 where 
the aromatic rings of danoprevir and TMC435 stack against the guanidinium group of 
R155 (Figure 3.4).  This molecular interaction alters the electrostatic network involving 
R123, D168, R155, and D81.  R155 rotates nearly 180° around Cδ relative to its 
conformation observed in product complexes, losing its hydrogen bond with D81 but 
maintaining interaction with D168.  Mutations at R155 or D168 would disrupt the 
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Figure 3.4:  Stereo view of protease inhibitors in the substrate envelope.  (A) After 
active site superpositions, the overlapping vdW volume shared by any three of the four 
cleavage products defines the substrate envelope, depicted in blue.  Protease residues that 
mutate to confer drug resistance are shown in brown.  (B) Danoprevir, (C) boceprevir and 
(D) TMC435 protrude from the substrate envelope at several locations, which correlate 
with known sites of drug resistance mutations to each inhibitor, shown in red.
107
108
 electrostatic network and destabilize this packing thereby lowering the affinity for these 
macrocyclic drugs.  This provides a structural rationale for the drug resistance mutations 
R155K, as previously proposed (19), and D168A/V, which both confer a selective 
advantage in vitro in the presence of danoprevir or TMC435 (26, 30).  In addition, the 
TMC435 complex reveals that R155 is stabilized by a hydrogen bond with Q80, which 
also mutates to confer resistance to TMC435 (30).  Thus many of the primary drug 
resistance mutations can be explained by the disruption of the interactions involving the 
functional groups at P2 of the drugs. 
Insights into drug resistance 
To determine the locations where the inhibitors protrude from the substrate 
envelope, the inhibitor and product complexes were also superposed using residues 137–
139 and 154–160.  The vdW volumes of inhibitor protrusion from the substrate envelope 
(Vout) (44, 45) were calculated for each drug and compared with published EC50 fold-
change data for drug resistance variants (30).  The P2 moieties of boceprevir, danoprevir 
and TMC435 protrude most extensively from the substrate envelope with Vout values of 
105, 294 and 496Å3, respectively (Table 3.4).  The magnitudes of the EC50 fold-change 
data determined for each NS3/4A mutant generally trend with the Vout values for the 
three drugs. 
However, the precise level of drug resistance observed is also determined by the 
particular change in molecular interaction occurring for a given mutation.  A156 and 
R155 pack with the P2 moieties of these three inhibitors where they protrude beyond the 
substrate envelope.  Mutations of A156 to bulkier side chains would result in a steric 
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 Table 3.4.  Drug activities† and volume of protrusion from the substrate envelope (Vout). 
  Boceprevir Danoprevir TMC435 
Subsite Resistance Mutation Vout (Å
3) EC50 FC Vout (Å3) EC50 FC Vout (Å3) EC50 FC 
Total  292  500  649  
P1  76  67  64  
P2  105  294  496  
 Q80R  0.5  3.5  6.9 
 Q80K  0.8  2.3  7.7 
 R155K  4.7  447  30 
 A156V  75  63  177 
 A156T  65  41  44 
 D168A  0.7  153  594 
 D168E  0.8  75  40 
P3  34  70  67  
P4  76  69  0  
 V158I  3.3‡  ND  ND 
†- Antiviral activity was reported previously by Lenz et al., 2010. 
‡- Fold-change in EC50 reported in replicon assay by Qiu et al., 2009. 
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 clash with the P2 drug moieties.  For example, the rigid dimethylcyclopropane group of 
boceprevir protrudes from the substrate envelope at the P2 subsite, and A156V or A156T 
confer 65 and 75 fold-changes in EC50, respectively (Table 3.4).  Similarly, molecular 
changes at R155 and D168 would result in a substantial loss of interactions with P2.  The 
most extensive protrusions of danoprevir and TMC435 at P2 trend with their greatest 
fold-change in potency of nearly 450 and 600, respectively, from mutations in this 
subsite.  Thus the extent by which an inhibitor protrudes from the substrate envelope in a 
given subsite is indicative of the inhibitor’s vulnerability to drug resistance. 
Further structural analyses with the substrate envelope provide insights into other 
NS3/4A drug resistance mutations.  The P1' sulfonamide groups of danoprevir and 
TMC435, as well as the P1' ketoamide of boceprevir, protrude from the substrate 
envelope near residues Q41 and F43, which both mutate to confer low-level resistance to 
these drugs (25, 30, 56).  The keto group of boceprevir also projects outside the substrate 
envelope near T54 and V55.  T54A/S confers low-level resistance to boceprevir, while 
V55A was recently identified in patient isolates after treatment with boceprevir (57).  The 
analogous carbonyl groups of danoprevir and TMC435, however, are orientated in the 
opposite direction and protrude toward S138.  In fact, in vitro studies reveal reduced 
activity for danoprevir and TMC435 against S138T variants, while boceprevir remains 
fully active (30, 56).  The bulky P4 tert-butyl group of boceprevir extends outside the 
substrate envelope contacting V158; V158I variant has lower affinity, likely due to a 
steric clash (58).  This variant may also impact the affinity of danoprevir, as its P4 tert-
butyl also protrudes at the same location.  These findings demonstrate that in regions 
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 outside the P2 subsite, positions where danoprevir, TMC435 and boceprevir protrude 
from the substrate envelope also correlate with many other known sites for drug 
resistance mutations.   
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 DISCUSSION 
The emergence of drug resistance is a major obstacle in modern medicine that 
limits the long-term usefulness of the most promising therapeutics. By considering how 
HCV NS3/4A protease inhibitors bind relative to natural viral substrates, we discovered 
that primary sites of resistance occur in regions of the protease where drugs protrude 
from the substrate envelope.  In particular, R155 and A156, which mutate to confer 
severe resistance against danoprevir, TMC435 and boceprevir, interact closely with the 
P2 drug moieties where they protrude most extensively from the substrate envelope.  
Molecular changes at these residues confer resistance by selectively weakening inhibitor 
binding without compromising the binding of viral substrates.  We further speculate that 
these mutations will not considerably affect the binding of the host cellular substrates 
TRIF and MAVS, which likely fit well within the substrate envelope as they share many 
features with the viral substrates.  However, TRIF contains a tract of eight proline 
residues instead of an acidic residue at position P6, which may modulate its binding.  
Further structural studies are warranted to better ascertain the molecular details of how 
these cellular substrates are recognized by the NS3/4A protease.  
Although this study focuses on danoprevir, TMC435 and boceprevir, other 
NS3/4A protease inhibitors in clinical trials, including telaprevir, narlaprevir and 
vaniprevir (Figure 3.1A), contain similar functional groups that likely protrude from the 
substrate envelope.  Most notably, all these drug candidates contain bulky P2 moieties 
and are therefore susceptible to cross-resistance against mutations at R155 and A156.  
R155 and A156 mutations have been shown to confer telaprevir resistance in treated 
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 patients (59).  Cross-resistance studies have also shown that narlaprevir displays similar 
fold losses in activity against most of the known drug resistance mutations for telaprevir 
and boceprevir (60).  Ultimately, to slow the emergence of multi-drug resistant viral 
strains, inhibitors should be confined within the substrate envelope, particularly at the P2 
position.  To compensate for the loss of binding affinity that will likely accompany these 
changes, additional interactions could potentially be optimized spanning the S4–S6 
subsites of the protease and the catalytic triad. 
Our findings further suggest a general model for using the substrate envelope to 
predict patterns of drug resistance in other quickly evolving diseases.  For drug resistance 
to occur, mutations must selectively weaken target affinity for an inhibitor without 
significantly altering its natural biological function.  Mutations occurring outside the 
substrate envelope are better able to achieve this effect, as these molecular changes can 
selectively impair inhibitor binding without compromising substrate recognition.  When 
the interaction of a drug target with its biological substrates can be structurally 
characterized, we predict that drugs contained within the substrate envelope will be less 
susceptible to resistance.  Structure-based design strategies can utilize this model as an 
added constraint to develop inhibitors that fit within the substrate envelope.  In fact, 
previous work in our laboratory provides proof-of-concept for the successful 
incorporation of the substrate envelope in the design of novel HIV protease inhibitors, 
which maintain potent activities against a series of highly resistant HIV strains (45, 61-
66).  As a general paradigm, substrate envelope-based design efforts can facilitate the 
rationale development of drug candidates that are less susceptible to resistance. 
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 ABSTRACT 
Hepatitis C virus infects 180 million people worldwide but antiviral therapies are 
only effective for a subset of patients.  Despite extensive efforts to develop inhibitors 
targeting the essential viral NS3/4A protease, the rapid acquisition of resistance 
challenges the long-term efficacy of this drug class.  We determined high-resolution 
crystal structures of four chemically diverse protease inhibitors – telaprevir, danoprevir, 
vaniprevir and MK-5172 – in complex with the wildtype protease and three major drug 
resistant variants.  The drugs exhibit differential susceptibilities to these mutations; 
telaprevir, danoprevir and vaniprevir interact directly with sites that mutate to confer 
resistance, while MK-5172 interacts in a unique conformation with the catalytic triad.  
This novel mode of MK-5172 binding explains its retained potency against two multi-
drug resistant variants, R155K and D168A.  Together our findings define the molecular 
basis of HCV N3/4A protease inhibitor resistance, providing a direct strategy for 
designing robust therapies against this rapidly evolving virus. 
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 INTRODUCTION 
Hepatitis C virus (HCV) infects an estimated 180 million people worldwide and is 
the leading cause for liver transplantation in the United States (1, 2).  The HCV genome 
encodes a single polyprotein that is cleaved into structural (C, E1, E2, p7) and non-
structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins by host cell and viral 
proteases (3).  The viral NS3/4A protease, a chymotrypsin-like serine protease, is a prime 
therapeutic target that cleaves four known sites along the polyprotein (4, 5).  The NS3/4A 
protease also hydrolyzes two human proteins of the innate immune system, TRIF and 
MAVS, thereby confounding the immune response to viral infection (6, 7).  
Pharmaceutical companies have invested considerable resources in the development of 
NS3/4A protease inhibitors.  Proof-of-concept for the efficacy of this drug class was first 
demonstrated in 2004 by the inhibitor ciluprevir (8, 9), though later discontinued due to 
cardiotoxicity (10).  Many other protease inhibitors have since advanced into later stages 
of human clinical trials (Figure 4.1).  The Food and Drug Administration recently 
approved the protease inhibitors telaprevir and boceprevir for clinical use in combination 
with ribavirin and pegylated interferon-α, marking an important milestone in antiviral 
research and drug development over the past two decades.   
HCV replicates rapidly in untreated individuals, producing an estimated one 
trillion virus particles daily (11, 12).  Viral replication is inherently error-prone and 
misincorporation of bases leads to genetically diverse virus populations over time, known 
as quasispecies (13).  As patients begin antiviral treatment, selective drug pressures favor 
resistant viral strains, particularly in the setting of monotherapy (14).  To reduce the 
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Figure 4.1:  The chemical structures of nine NS3/4A protease inhibitors.  The 
canonical nomenclature for drug moiety positioning is indicated using telaprevir.  
Telaprevir, danoprevir, vaniprevir and MK- 5172 are representative of many other 
protease inhibitors in development.  Telaprevir, recently approved for clinical use, is an 
acyclic ketoamide inhibitor that forms a reversible, covalent bond with the protease.  
Danoprevir, currently in phase II clinical trials, is a sulfonamide inhibitor with a P1–P3 
macrocycle.  Vaniprevir and MK-5172 are also sulfonamide inhibitors, but contain P2–
P4 macrocycles.  Vaniprevir and MK-5172 differ in the construction of their P2* 
moieties: vaniprevir contains a carbamate linkage between the P2 proline and P2* 
isoindoline moiety, whereas MK-5172 contains a shorter ether linkage between its P2 
proline and P2* quinoxaline moiety.
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 likelihood of resistance, treatment regimens utilize combination therapies that limit viral 
evolution through several distinct mechanisms simultaneously.  However, combination 
therapy with ribavirin and pegylated interferon-α is only effective for a subset of patients, 
depending on both human and viral genetic factors (15-19).  Sustained treatment 
adherence also remains a critical predictor for treatment outcome, as suboptimal dosing 
allows for the selection of drug resistant viral variants (20).  Adverse drug effects, 
including flu-like symptoms, depression and anemia, are commonly reported and often 
hinder the successful completion of full-dose treatment regimens (20, 21).  Though high 
treatment completion rates are reported in clinical trials, these patients are routinely 
screened prior to enrollment and actively supported throughout therapy to maximize 
adherence (22).  However, several small cohort studies report completion rates as low as 
50% in the clinical setting, highlighting the impact of disease co-morbidities, 
socioeconomic status, emotional support and related factors on treatment outcome (23, 
24).  Although new antiviral agents are becoming available, dominant polymerase and 
protease inhibitor resistance mutations have been detected in treatment naïve individuals, 
indicating that drug resistant strains may be directly transmissible(25).  Thus despite the 
benefits of combination therapy in limiting viral evolution, the emergence of drug 
resistance still challenges the long-term efficacy of antiviral therapies in the clinic.  
The rapid rise of resistance has reduced the efficacy of the most potent NS3/4A 
protease inhibitors in human clinical trials.  Most notably, single site mutations at 
residues R155, A156 and D168 confer multi-drug resistance (26-31).  In this study, four 
chemically diverse protease inhibitors – telaprevir, danoprevir, vaniprevir and MK-5172 
128
 – exhibit distinct susceptibilities to the protease variants R155K, D168A and A156T 
(Table 4.1).  Sixteen high-resolution crystal structures of the wildtype protease and these 
drug resistant variants reveal the molecular basis underlying the resistance profiles of 
these four drugs (Table 4.2).  The A156T mutation clashes with all four drugs, although 
flexibility in danoprevir accommodates this clash.  The R155K mutation confers 
telaprevir resistance by reducing drug packing with this protease variant.  The R155K and 
D168A mutations also confer resistance to danoprevir and vaniprevir by disrupting 
favorable stacking interactions.  In contrast, MK-5172 packs against the catalytic triad in 
a novel conformation, explaining its retained potency against R155K and D168A.  Taken 
together, the differential drug susceptibilities to these major mutations arise from unique 
drug interactions, highlighting direct strategies for designing novel protease inhibitors 
that are highly potent but less susceptible to resistance. 
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 Table 4.1.  NS3/4A protease inhibitor activities from enzymatic inhibition experiments and drug 
susceptibility assays against wildtype protease and variants R155K, D168A and A156T. 
 Ki (nM) Drug Susceptibilities - IC50† (nM) 
Drug WT WT R155K D168A A156T 
Telaprevir 66 ± 3 1030 5300 (5.1) 420 (0.4) >50,000 (>49) 
Danoprevir 0.46 ± 0.03 0.24 >100 (>416) 48 (200) 5.7 (24) 
Vaniprevir 0.13 ± 0.02 0.34 >400 (>1176) >400 (>1176) 176 (518) 
MK-5172 0.0024 ± 0.005 0.11  0.55 (5) 13 (118) 108 (982) 
† – Numbers in parentheses reflect fold-change relative to wildtype. 
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 MATERIALS AND METHODS 
Reagent synthesis, purchase and storage 
Danoprevir was synthesized using the convergent reaction scheme described 
previously (32).  Vaniprevir and MK-5172 were prepared following the previously 
published procedures (33, 34).  One hundred milligrams of telaprevir were purchased 
from A ChemTek, Inc. (Worcester, MA).  All drugs were reconstituted in DMF to a final 
concentration of 30mM and placed at −20ºC for storage.  Thirty milligrams of the 
previously reported peptide inhibitor (DE-Dif-I-Cha-C) (35) were purchased from 21st 
Century Biochemicals (Marlboro, MA) at 95% purity with 5-carboxyfluorescein 
covalently bonded to the N-terminus.  The purity was confirmed by HPLC and mass 
spectrometry profiles provided by the company.  The fluorescent peptide probe was 
stored as a solid at −20ºC and dissolved in reaction buffer to a final concentration of 5–
15nM for competition experiments.  
Mutagenesis and gene information 
The HCV genotype 1a NS3/4A protease gene described in a Bristol-Meyers 
Squibb patent (36) was synthesized by GenScript and cloned into the pET28a expression 
vector (Novagen).  The gene encodes a highly soluble form of the NS3/4A protease 
domain as a single-chain, with 11 core amino acids of NS4A located at the N-terminus.  
The protease variants S139A, R155K, D168A and A156T were subsequently constructed 
using the QuikChange site-directed mutagenesis kit from Stratagene and sequenced by 
Davis Sequencing for confirmation. 
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 Expression and purification of NS3/4A protease constructs 
Protein expression and purification were carried out as described previously (36, 
37).  Briefly, transformed BL21(DE3) E. coli cells were grown at 37ºC and induced at an 
optical density of 0.6 by the addition of 1mM IPTG.  Cells were harvested after 5 hours 
of expression, pelleted and frozen at −80ºC for storage.  Cell pellets were thawed, 
resuspended in 5mL/g of resuspension buffer (50mM phosphate buffer at pH 7.5, 500mM 
NaCl, 10% glycerol, 2mM β-ME) and lysed with a cell disruptor.  The soluble fraction 
was retained, applied to a nickel column (Qiagen), washed with resuspension buffer, and 
eluted with resuspension buffer supplemented with 200mM imidazole.  The eluant was 
dialyzed overnight (MWCO 10kD) to remove the imidazole and the his-tag was 
simultaneously removed with thrombin treatment.  The nickel-purified protein was then 
flash-frozen and stored at −80ºC for up to six months.   
Crystallization of inhibitor complexes 
For crystallization, the protein solution was thawed, concentrated to ~3mg/mL 
and loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer 
(25mM MES at pH 6.5, 500mM NaCl, 10% glycerol, 30µM zinc chloride, and 2mM 
DTT).  The protease fractions were pooled and concentrated to 20–25mg/mL with an 
Amicon Ultra-15 10kD device (Millipore).  The concentrated samples were incubated for 
one hour with 1–3 molar excess of inhibitor.  Diffraction-quality crystals were obtained 
overnight by mixing equal volume of concentrated protein solution with precipitant 
solution (20–26% PEG-3350, 0.1M sodium MES buffer at pH 6.5, and 4% ammonium 
sulfate) in 24-well VDX hanging drop trays. 
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 Data collection and structure solution  
Crystals large enough for data collection were flash-frozen in liquid nitrogen for 
storage.  Crystals were mounted under constant cryostream and X-ray diffraction data 
were collected at Advanced Photon Source LS-CAT 21-ID-F, GM/CA-CAT 23-ID-D or 
our in-house RAXIS IV X-ray system.  Diffraction intensities were indexed, integrated 
and scaled using the program HKL2000 (38).  All structure solutions were generated 
using simple isomorphous molecular replacement with PHASER (39).  The B chain 
model of viral substrate product 4A4B (3M5M) (32) was used as the starting model for 
all structure solutions.  Initial refinement was carried out in the absence of modeled 
ligand, which was subsequently built in during later stages of refinement.  Upon 
obtaining the correct molecular replacement solutions, subsequent crystallographic 
refinement was carried out within the CCP4 program suite with iterative rounds of TLS 
and restrained refinement until convergence was achieved (40). Amplitude-based twinned 
refinement was carried out for all pseudo-merohedral twins (crystal complexes with MK-
5172 with the exception of A156T).  The final structures were evaluated with MolProbity 
(41) prior to deposition in the protein data bank.  5% of the data was reserved for the free 
R-value calculation to limit the possibility of model bias throughout the refinement 
process (42).  Interactive model building and electron density viewing was carried out 
using the program COOT (43). 
Inhibitor complex analysis and the substrate envelope 
All active site alignments were performed in PyMOL using the Cα atoms of 
protease residues 137–139 and 154–160.  For each alignment, the wildtype-danoprevir 
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 complex was used as the reference structure.  The viral substrate envelope – representing 
the consensus vdW volume shared by any three of the four viral substrate products – was 
computed as described previously using the full-length NS3/4A structure (1CU1) (44) 
and product complexes 4A4B (3M5M), 4B5A (3M5N) and 5A5B (3M5O) (32). 
Drug susceptibility assays 
Single mutations (R155K, D168A, or A156T) were introduced into the NS3 
region of an HCV Con1 luciferase reporter replicon using the mega-primer method of 
mutagenesis(45).  Replicon RNA of each protease variant was introduced into Huh7 cells 
by electroporation.  Replication was then assessed in the presence of increasing 
concentration of protease inhibitors (telaprevir, danoprevir, vaniprevir or MK-5172) by 
measuring luciferase activity (relative light units) 96 hours after electroporation.  The 
drug concentrations required to inhibit replicon replication by 50% (IC50) were calculated 
directly from the drug inhibition curves.  
Enzymatic inhibition assays 
For enzymatic inhibition experiments, 5nM of the NS3/4A protease domain or 
full-length protein were incubated with increasing amounts of drug for 15 minutes (90 
minutes for telaprevir) in 25mM Tris (pH 7.5), 2.5% glycerol, 5mM TCEP, 0.1% OβG 
and 2% DMSO.  Proteolysis reactions were initiated by the addition of 200nM of 
fluorogenic substrate RET S1(46) (AnaSpec) and monitored using the EnVision plate 
reader (Perkin Elmer) at excitation and emission wavelengths of 340nm and 490nm, 
respectively.  The initial cleavage velocities were determined from sections of the 
progress curves corresponding to less than 15% substrate cleavage.  Drug inhibition 
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 constants (Ki) were obtained by nonlinear regression fitting to the Morrison equation of 
initial velocity versus inhibitor concentration using Prism (GraphPad Software).  Data for 
each drug were generated in triplicate and processed independently to calculate the 
average inhibition constant and standard deviation. 
VdW contact energy 
VdW contact energies between protease residues and peptide products were 
computed using a simplified Lennard-Jones potential as described previously(47).  
Briefly, the Lennard-Jones potential (Vr) was calculated for each protease-drug atom pair 
where r, ε and σ represent the interatomic distance, vdW well depth and atomic diameter, 
respectively: 
 
 
 
Vr was computed for all possible protease-drug atom pairs within 5Å, and potentials for 
non-bonded pairs separated by less than the distance at the minimum potential were 
equated to −ε.  Using this simplified potential value for each non-bonded protease-
product atom pair, the total vdW contact energy was computed for each peptide residue.  
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 RESULTS 
The Substrate Envelope 
The wildtype drug complexes were analyzed with the substrate envelope to 
characterize drug interactions relative to natural substrate products (Figures 4.2A–4.5A).  
The substrate envelope was constructed as reported previously and represented the 
volume shared by any three of the four N-terminal viral substrate products (32).  
Superposition of the drug complexes revealed that the four inhibitors protruded from the 
substrate envelope in a region termed the P2 subsite, packing against residues R155, 
A156 and D168.  The relatively small P2 cyclopentylproline moiety of telaprevir 
interacted less extensively with these residues relative to the other drugs, which contain 
bulkier P2* moieties.  The carbamate-linked P2* isoindoline moieties of danoprevir and 
vaniprevir formed cation-π stacking interactions with R155, and also interacted 
extensively with A156 and D168.  The isoindoline moiety of danoprevir bound in two 
conformations to the wildtype protease, with its fluorine atom oriented either towards the 
catalytic triad or the P2 subsite.  The P2* moiety of vaniprevir adopted just one 
conformation and formed greater interactions with D168 due the positioning of its C4 
methylene linker in the P2–P4 macrocycle.  The longer C5 methylene linker in the P2–P4 
macrocycle of MK-5172 extended away and thus contributed less van der Waals (vdW) 
contact with D168.  Notably, the ether-linked P2* quinoxaline moiety of MK-5172 
protruded uniquely from the substrate envelope towards the catalytic triad, avoiding 
direct contact with R155 and D168.  Thus these drugs make different interactions with 
the protease outside the substrate envelope, and molecular changes in these regions can 
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Figure 4.2:  Stereo view of the telaprevir complexes.  (A) Telaprevir is shown bound to 
the wildtype protease with the substrate envelope in blue.  Telaprevir is also shown 
bound to the drug-resistant variants (B) R155K, (C) D168A and (D) A156T with the 
transparent coordinates representing the wildtype structure to better highlight the 
molecular changes of each mutation.  In all cases, catalytic residues are depicted in 
yellow, the P2 subsite in pink, and the drug molecules in orange. 
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 facilitate resistance by selectively disrupting drug binding without substantially affecting 
the recognition and processing of authentic viral substrates. 
Wildtype Drug Binding 
Danoprevir, vaniprevir and MK-5172 bound with similar affinities to the wildtype 
protease, while telaprevir binding was 15–20 fold weaker (Table 4.1).  Many structural 
features underlying these affinities were common for all drug complexes.  For example, 
the four drugs made the same three hydrogen bonds with the protease backbone (Table 
4.3): (i) the P1 amide nitrogen with the carbonyl oxygen of R155, (ii) the P3 carbonyl 
oxygen with the amide nitrogen of A157, and (iii) the P3 amide nitrogen with the 
carbonyl oxygen of A157.  The P5 amide nitrogen of telaprevir formed an additional 
hydrogen bond with the carbonyl oxygen of S159.  In the telaprevir complex, the 
ketoamide oxygen sat in the oxyanion hole and interacted with the backbone amide 
nitrogens of protease residues 137–139, while the Nε nitrogen of H57 hydrogen bonded 
with the keto oxygen (Figure 4.2A).  The sulfonamide groups of danoprevir, vaniprevir 
and MK-5172 were also positioned in the oxyanion hole, hydrogen-bonding with the 
same set of backbone nitrogens as the macrocyclic drugs.  Meanwhile the Nε nitrogen of 
H57 interacted with the sulfonamide nitrogen in these complexes, suggesting that the Nε 
atoms were deprotonated in these complexes (Figure 4.3A–4.5A). 
Mechanisms of Drug Resistance  
Drug susceptibility data and high-resolution crystal structures were utilized to 
analyze the sixteen combinations of wildtype and multi-drug resistant protease variants 
with the four protease inhibitors: telaprevir, danoprevir, vaniprevir and MK-5172. 
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Table 4.3.  Drug hydrogen bonds (Hbonds) and vdW contacts with wildtype protease. 
Moiety Telaprevir Danoprevir Vaniprevir MK-5172 
 Hbonds vdW Hbonds vdW Hbonds vdW Hbonds vdW 
P1' 
G137 
S138 
S139 
Q41 
T42 
F43 
K136 
G137 
S138 
S139A 
Q41 
T42 
F43 
K136 
G137 
S138 
S139A 
Q41 
T42 
F43 
K136 
G137 
S138 
S139A 
Q41 
T42 
F43 
K136 
P1 H57 R155 F154 
H57 
R155 F154 
H57 
R155 F154 
H57 
R155 F154 
P2  
R155 
A156 
D168 
 
R155 
A156 
D168 
D79 
K80 
 
R155 
A156 
D168 
D79 
K80 
 
Y56 
H57 
D81 
R155 
A156 
P3 A157† 
I132 
L135 
A157 
A157† 
I132 
L135 
A157 
A157 
I132 
L135 
A157 
A157 
I132 
L135 
A157 
P4  
R123 
A156 
V158 
D168 
 A156 D168  
R123 
D168  
R123 
V158 
P5  S159 ∂ ∂ ∂ ∂ ∂ ∂ 
†- Contributes two hydrogen bonds  
∂- Inhibitors do not contain P5 moiety 
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Figure 4.3: Stereo view of the danoprevir complexes.  (A) Danoprevir is shown bound 
to the wildtype protease with the substrate envelope in blue.  Danoprevir is also shown 
bound to the drug-resistant variants (B) R155K, (C) D168A and (D) A156T with the 
transparent coordinates representing the wildtype structure to better highlight the 
molecular changes of each mutation.  In all cases, catalytic residues are depicted in 
yellow, the P2 subsite in pink, and the drug molecules in orange.
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 § Telaprevir resistance 
Telaprevir bound to the R155K variant in a conformation similar to the wildtype 
complex (Figure 4.2B).  However, this mutation lost considerable vdW contact with 
telaprevir (Figure 4.6A) and also disrupted the electrostatic network spanning R123, 
D168, R155 and D81, forming along the drug binding surface in the wildtype complex.  
Specifically, R155K no longer interacted with D168, which rotated slightly to maintain 
contact with R123.  These rearrangements disrupted the charge landscape along this 
surface of the protease, which in turn disrupted interactions with the P2 
cyclopentylproline and P4 cyclohexylalanine moieties of telaprevir.   Thus these 
structural changes disrupt many features observed in the wildtype telaprevir complex, 
explaining the 5-fold reduction in telaprevir potency against R155K in drug susceptibility 
assays (Table 4.1). 
The D168A mutant complex revealed a complete shift of telaprevir by 
approximately 0.5Å relative to its wildtype conformation (Figure 4.2C).  The P2 
cyclopentylproline moiety of telaprevir bent considerably towards D168A, resulting in 
increased vdW interaction with both R155 and A156.  These structural changes also 
reduced vdW contact with H57, but this catalytic base still maintained its hydrogen bond 
with the keto oxygen of the ketoamide group.  The altered packing of telaprevir increased 
interactions in the P2 subsite, explaining its enhanced potency against the D168A in drug 
susceptibility assays (Table 4.1). 
The A156T-telaprevir complex revealed in a direct clash between A156T and the 
P2 cyclopentylproline, causing the position of telaprevir to shift relative to the wildtype 
144
 (Figure 4.2D).  H57 also shifted to maintain its hydrogen bond with the keto oxygen of 
the ketoamide group.  The P2 cyclopentylproline of telaprevir moved away from R155, 
losing considerable vdW contact with the drug.  In addition, the nucleophilic oxygen of 
S139 was over 2Å from the keto carbon of the ketoamide group of telaprevir.  Although 
this carbon was modeled in the tetrahedral state, indicating covalent bond formation with 
the protease, this increased inter-atomic distance suggested that the electron density was 
the average of the tetrahedral state and the planar state of the unmodified drug form.  
Thus the A156T mutation reduced the capacity of telaprevir to react covalently with the 
catalytic S139, contributing considerably to the loss in potency.  These structural changes 
are consistent with the large fold-loss in potency of telaprevir against the A156T variant 
(Table 4.1). 
§ Danoprevir and vaniprevir resistance 
The P2* moieties of danoprevir and vaniprevir shifted in the R155K complexes 
relative to the wildtype coordinates, disrupting the favorable cation-π stacking 
interactions observed in the wildtype complex (Figure 4.3B).  Danoprevir bound in only 
one conformation to the R155K variant with the fluorine of its isoindoline moiety 
orientated towards the P2 subsite.  In both drug complexes, R155K lost considerable 
vdW interactions with the P2* isoindoline moieties relative to the wildtype coordinates 
(Figure 4.6B).  Although these changes also caused greater vdW interactions with H57 
and D81, these gains did not compensate fully for the disruption of the favorable cation-π 
stacking between R155 and the aromatic rings of the P2* moieties.  Indeed, these 
structural observations are consistent with the 400-fold reductions in potency of 
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 danoprevir and vaniprevir against the R155K variant (Table 4.1). 
In the D168A complexes, the P2* isoindoline moieties of danoprevir and 
vaniprevir also shifted towards D81 of the catalytic triad, thereby disrupting the cation-π 
stacking interactions observed in the wildtype complexes (Figure 4.4C).  The 4-
fluoroisoindoline moiety of danoprevir also adopted just one conformation in the D168A 
complex.  The D168A mutation also reduced the drug vdW interactions with due to the 
smaller volume of alanine compared to aspartate.  However, these structural changes 
were minor relative to the large losses in potency caused by this mutation (Table 4.1).  
Other molecular forces, such as electrostatics, may play crucial roles in the binding of 
danoprevir and vaniprevir.  In particular, the electrostatic interactions between R155 and 
D168, observed in the wildtype complexes, may stabilize R155 for optimal cation-π 
stacking with the P2* isoindoline moieties.  Thus the D168A mutation may disrupt these 
interactions without substantially altering the bound drug conformations (Table 4.1). 
In both A156T complexes, the P2* moieties of danoprevir and vaniprevir shifted 
away from the P2 subsite and toward the catalytic triad.  The shifted positioning of the 
P2* moieties directly disrupted the cation-π stacking interactions with R155, observed in 
the wildtype complexes.  The Oγ oxygens of A156T also formed hydrogen bonds with 
D168 in both drug complexes, which by competing for interaction with D168, may 
indirectly disrupt the cationic of R155 necessary for optimal stacking with the P2* 
isoindoline moieties.  As in the other mutant complexes, the 4-fluoroisoindoline moiety 
of danoprevir adopted just one conformation in the A156T complex.  However, the 
flexibility of the P2* moiety of danoprevir allowed for its large shift and retained packing 
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Figure 4.4: Stereo view of the vaniprevir complexes.  (A) Vaniprevir is shown bound 
to the wildtype protease with the substrate envelope in blue.  Vaniprevir is shown bound 
to the drug-resistant variants (B) R155K, (C) D168A and (D) A156T with the transparent 
coordinates representing the wildtype structure to better highlight the molecular changes 
of each mutation.  In all cases, catalytic residues are depicted in yellow, the P2 subsite in 
pink, and the drug molecules in orange. 
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 against A156T, partially compensating for the steric burden of this mutation (Figure 
4.3D).  In contrast, the P2–P4 macrocycle of vaniprevir restrained its ability to 
accommodate this steric burden, consistent with the smaller shift of its P2* moiety 
relative to that of danoprevir.  Thus the rigidity of the P2* moiety of vaniprevir likely 
minimizes its compensatory potential, explaining its 500-fold loss in potency against the 
A156T variant, while danoprevir remained highly active against this protease variant 
(Table 4.1). 
§ MK-5172 resistance 
R155 and D168 did not interact extensively with the P2* quinoxaline moiety of 
MK-5172 in the wildtype complex.  Thus single mutations at these residues, R155K or 
D168A, did not substantially alter drug binding (Figures 4.5B and 4.5C).  In fact, 
R155K contributed more vdW contact with MK-5172 relative to R155 in the wildtype 
complex (Figure 4.6D).  The less bulky R155K also allowed for a slight shift of MK-
5172 toward the catalytic triad, resulting in increased vdW contact of the P2* moiety with 
A156, D81 and H57.  Similar changes were observed in the D168A complex, although 
this mutation also led to an extended conformation of R123 in this case, losing vdW 
contact with the P4 cyclopropyl moiety of MK-5172.  The slight loss in potency of MK-
5172 against D168A likely arose from this minor loss in contact energy.  Nevertheless, 
these structural changes explain the high potency of MK-5172 against the R155K and 
D168A protease variants in drug susceptibility assays (Table 4.1). 
The A156T mutation resulted in a steric clash with the benzylic methylene of the 
P2–P4 macrocycle of MK-5172, causing the drug to shift considerably relative to the 
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Figure 4.5:  Stereo view of the MK-5172 complexes.  (A) MK-5172 is shown bound to 
the wildtype protease with the substrate envelope in blue.  MK-5172 is shown bound to 
the drug-resistant variants (B) R155K, (C) D168A and (D) A156T with the transparent 
coordinates representing the wildtype structure to better highlight the molecular changes 
of each mutation.  In all cases, catalytic residues are depicted in yellow, the P2 subsite in 
pink, and the drug molecules in orange. 
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 wildtype coordinates (Figure 4.5D).  H57 also shifted by the same magnitude to maintain 
its hydrogen bond with the amide nitrogen of the sulfonamide group.  Despite increased 
vdW contact with A156T (due to steric volume), these changes also caused losses in vdW 
contact with D81 and R155.  Together these structural changes explain the 50-fold loss in 
potency of MK-5172 against the A156T (Table 4.1). 
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Figure 4.6: Drug vdW interactions in wildtype and mutant complexes.  The vdW 
energy indexes for the wildtype protease and mutant variants R155K, D168A and A156T 
are shown by residue for (A) telaprevir, (B) danoprevir, (C) vaniprevir and (D) MK-5172. 
 
153
154
 DISCUSSION 
Drug resistance challenges the long-term effectiveness of anti-HCV therapies, 
highlighting the need for novel inhibitors that are less susceptible to resistance.  Despite 
considerable advances in the development of NS3/4A protease inhibitors, the rapid rise of 
resistance has limited the efficacy of many potent drugs in this class (26-31).  By 
determining sixteen high-resolution crystal structures, we have elucidated the molecular 
basis of drug resistance against four chemically diverse protease inhibitors: telaprevir, 
danoprevir, vaniprevir and MK-5172.  These drugs exhibit unique patterns of resistance 
against the multi-drug resistant variants R155K, D168A and A156T.  The A156T 
mutation substantially reduces the potencies of telaprevir, vaniprevir and MK-5172 
through steric clashes.  In contrast, the mobility of the P2* isoindoline moiety of 
danoprevir – not restrained by a P2–P4 macrocycle – allows its retained potency against 
this variant.  The R155K and D168A mutations also confer resistance to danoprevir and 
vaniprevir by disrupting favorable cation-π stacking interactions of R155 with their P2* 
isoindoline moieties.  Telaprevir displays enhanced potency against D168A through 
increased packing in the P2 subsite, but loses potency against R155K through decreased 
packing.  In contrast to the other drugs, the P2* quinoxaline moiety of MK-5172 adopts in 
a unique conformation and interacts with H57 and D81 of the catalytic triad, rather than 
residues R155 and D168.  This novel mode of MK-5172 binding explains its robust 
activity against the R155K and D168A variants, as MK-5172 potency derives from 
contacting residues of the catalytic triad that are essential for HCV NS3/4A protease 
function.  
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 Our results also provide predictions of drug activities against other genotypes and 
strains.  Genotype 3 viruses contain the NS3 protease residues Q168 and T123, instead of 
D168 and R123 found in other genotypes.  We predict that the terminal amide group of 
Q168 will be unable to stabilize R155 for stacking against the P2* moieties of danoprevir 
and vaniprevir, but may interact with T123 instead.  Thus we expect danoprevir and 
vaniprevir will exhibit reduced potencies against genotype 3 viruses, while MK-5172 will 
remain fully active.  In addition, for genotype 1 strains, our results indicate:  (i) MK-5172 
is active against R155K variants, (ii) telaprevir and MK-5172 are active against D168A 
variants, and (iii) danoprevir remains highly potent against A156T variants.  Thus as new 
inhibitors are developed and HCV resistance testing becomes more available, our 
findings can help guide anti-HCV treatment regimens for individual patients in the future. 
For drug resistance to occur against HCV protease inhibitors, mutations must 
selectively reduce drug binding without disrupting the recognition and cleavage of the 
natural viral substrates.  We show that most primary drug resistance mutations occur in 
regions of the protease outside the space normally occupied by natural viral substrates, 
defined as the substrate envelope.  Mutations in these regions of the protease selectively 
weaken drug binding without substantially compromising the recognition and cleavage of 
viral substrates.  Moreover, we demonstrate that inhibitors protruding from the substrate 
envelope must contact sites that are critical for catalytic activity.  The high potency of 
MK-5172, for example, derives from interactions with the NS3/4A catalytic triad, which 
cannot mutate without disrupting protease activity, and thus viral replication.  Future drug 
candidates that incorporate ether-linked P2* quinoxaline moieties, or related functional 
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 groups that pack on the catalytic triad, will likely retain potency against R155K and 
D168A variants.  In addition, drugs that incorporate adaptable P2* moieties, as in 
danoprevir, will better retain potency against the A156T mutation or other sterically 
bulky mutations.  Thus utilizing the substrate envelope, in combination with targeting the 
catalytic triad and incorporating flexibility in the P2* moieties, provides a focused 
approach for designing robust NS3/4A inhibitors that retain potency against a wide 
spectrum of drug resistant viral strains.   
Modern drug design strategies often utilize high-throughput screening and along 
with iterative analyses of the relationship of chemical structure to activity.  As these 
techniques focus primarily on disrupting target activity, drug potencies often derive from 
contacting residues that are not essential for target activity, which can mutate to confer 
resistance without altering biological function.  Indeed, the emergence of drug resistance 
is particularly concerning when treating HCV in the clinical setting, as drug side effects, 
disease co-morbidities, and many other factors limit patient adherence to antiviral 
therapy.  These high-resolution data, in conjunction with the substrate envelope, provide 
a powerful tool for the more rapid and rational evaluation of drug candidates in the face 
of drug resistance.   
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 THESIS IMPLICATIONS 
Rationally Evaluating Drug Candidates 
Modern drug design strategies often incorporate high-throughput screening in 
combination with structure-activity relationship (SAR) studies – analyses of the effect of 
chemical structure on activity.  These techniques focus primarily on disrupting target 
activity, and the resulting drugs often contact unessential target residues that can mutate 
without altering biological activity.  Thus alternative approaches – particularly in the face 
of target evolution – must exploit drug interactions with residues that are essential for 
target function.  MK-5172 exemplifies this approach by stacking extensively against the 
catalytic triad residues, which are strictly required for efficient protease activity.  When 
applicable, genetic analyses of target sequences can conveniently identify invariant 
residues across genotypes, subtypes or strains.  However, genetic invariance may not 
constitute functional necessity in the absence of selective drug pressures.  Thus 
mutational studies, such as alanine substitutions, are required to rigorously demonstrate 
the relative importance of specific residues to biological activity. 
Such mutational experiments, however, require time-consuming cloning and 
efficient assay systems.  Moreover, many target residues play intermediate roles and thus 
are not strictly required for activity.  The substrate envelope provides a practical 
alternative for evaluating drug candidates in the face of target evolution.  My research 
shows that resistance mutations arise in regions outside the substrate envelope, where 
NS3/4A protease extensively contacts drugs but not substrate products (1).  Thus the 
binding of drugs relative to the substrate envelope can predict their susceptibilities to 
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 resistance mutations.  Such analyses – performed with inhibitor crystal structures or 
computational models – are rapid and circumvent the need for laborious resistance testing 
in the early stages of development.  I hope that the substrate envelope becomes a useful, 
accessible tool for evaluating the clinical potential of novel HCV protease inhibitors in 
light of rapidly evolving resistance.
Designing Novel Protease Inhibitors 
Structure-based design strategies can incorporate the substrate envelope as a 
constraint in the construction of novel drug libraries.  In fact, our laboratory has extensive 
expertise in this area from the design project of HIV-1 protease inhibitors (2-5).  In 
theory, drugs designed to fit within the HCV substrate envelope will be less susceptible 
to resistance, as mutations disrupting drug binding will simultaneously reduce viral 
fitness by preventing substrate binding.  We can design novel compounds to fit within the 
substrate envelope by modifying scaffolds of the most potent drugs, such as danoprevir, 
vaniprevir and MK-5172.  SAR studies – comprising inhibitor crystal structures and 
activity assays – can assess the effects of various chemical substituents on drug potency 
and binding relative to the substrate envelope.  The best lead compounds can direct 
subsequent rounds of SAR studies, facilitating the discovery of more potent drug 
candidates that fit within the substrate envelope.  We can then perform drug susceptibility 
testing – in viral culture or replicon-based assays – to evaluate these drugs against major 
resistant HCV strains. 
The potencies of many NS3/4A protease inhibitors, however, derive from 
favorable interactions outside the substrate envelope, most notably in the P2 subsite (1, 6, 
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 7).  Thus constraining new compounds to fit within the substrate envelope will likely 
reduce their binding affinities.  Efforts must explore many substituents in parallel, 
including large P2 moieties, which may enhance drug potency despite protruding from 
the substrate envelope.  Specifically, the ether-linked P2 quinoxaline moiety of MK-5172 
should be incorporated in novel compounds, as it extends away from the P2 subsite and 
interacts with the catalytic residues H57 and D81.  Drug resistance mutations are unlikely 
to disrupt these interactions – despite their location outside the substrate envelope – 
because mutations at these catalytic sites would severely compromise viral fitness by 
disrupting proteolytic efficiency.  In addition, we should carefully consider and 
meticulously explore the location of macrocycles throughout the design process.  P2–P4 
macrocycles, like in vaniprevir and MK-5172, have rigidifying effects that increase 
susceptibility to bulky mutations at A156.  Drugs without P2 macrocycles, such as 
danoprevir, can better accommodate steric mutations due to the increased flexibility of its 
P2 substituent.  Ultimately, I hope substrate envelope-based SAR studies lead to the 
discovery of future generation NS3/4A protease inhibitors that remain active against 
highly resistant HCV variants.
Prime Side Substrate Interactions 
Inactive serine proteases – containing single, double or triple alanine mutations of 
the catalytic triad – still have residual catalytic activity (8).  Moreover, C-terminal 
substrate cleavage fragments diffuse from the active site and cannot be modeled in crystal 
structures (1, 9).  As a result, crystal structures only contain electron density for N-
terminal cleavage products, which bind to the protease active site with higher affinities 
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 than their parent substrates (10).  Thus the residual catalytic activity of inactive NS3/4A 
protease prevents the complete characterization of viral substrate binding.   
My research assumes that N-terminal cleavage products make the same 
interactions with the protease as non-cleaved substrates.  Though this assumption – in my 
opinion – is likely valid, it should be rigorously demonstrated by crystallizing the 
protease with non-hydrolyzable substrate mimics.  Non-cleavable P1–P1' dipeptide 
fragments will prevent NS3-mediated scissile bond hydrolysis.  Proline at P1' would most 
easily achieve this effect, although proline is not found naturally at this position and 
would kink in the peptide substrate.  Thus we should also explore two additional 
approaches:  (i) replacing the P1 amide bond with an azapeptide linkage, and (ii) 
incorporating P1–P1' aminomethylene or ketomethylene dipeptide isosteres.  
Characterizing the binding of these non-hydrolyzable substrate mimics would elucidate 
the interactions of C-terminal substrate residues, as well as N-terminal residues in the 
setting of full-length substrate binding.
Protease Dynamics and Substrate Recognition 
The crystal structures of substrate products, presented in Chapter II, raise 
questions about the role of protein dynamics in the substrate recognition.  The protease 
undergoes a conformational change upon binding certain substrate products, forming an 
extensive electrostatic network spanning residues H57, D81, R155, D168 and R123.  
These networks are absent in the crystal structures of products 4B5A and TRIF, however, 
which are less negatively charged relative to the other substrates.  Thus charge 
interactions may facilitate the recognition process of some – but not all – viral substrates.  
167
 NMR relaxation experiments of the unliganded and substrate-bound protease variants can 
probe changes in protein flexibility upon binding.  N15-labeled protease is highly soluble 
and easily expressed (11), making these experiments very feasible in our own laboratory.  
Relaxation experiments of drug-bound protease variants may also reveal differences in 
drug binding relative to authentic substrates, perhaps highlighting drug resistance 
mechanisms of non-active site mutations, such as V36M, T54A and V170A.  These 
experiments would complement our structural data, together providing a more 
comprehensive view of dynamic effects on protease function and drug resistance.
The Helicase Domain in Protease Function 
The helicase domain was shown to enhance NS3/4A proteolytic efficiency (12), 
although others groups report comparable catalytic efficiencies between full-length NS3 
and the protease domain alone (13, 14).  Alanine substitutions at residues Q526 and H528 
– positioned along the helicase interface with the protease active site – reduce the 
affinities of peptide inhibitors relative to the wildtype enzyme (15).  In addition, the 
helicase mutation S489L confers resistance against danoprevir, suggesting that the 
helicase domain influences drug binding (16).  Taken together, these findings implicate 
the helicase domain as a putative factor in substrate recognition and inhibitor binding. 
Substrate-bound crystal structures of full-length NS3 would most completely 
elucidate potential helicase domain interactions with the protease.  As such crystals are 
exceedingly difficult to grow, small-angle X-ray scattering and hydrogen-deuterium 
exchange experiments – on both bound and unbound states – may more reliably probe 
conformational NS3 ensembles.  Well-designed kinetic experiments can also provide 
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 detailed molecular views of domain interdependency.  Full-length NS3 may undergo 
autoinhibition by the 3-4A post-cleavage product, which remains bound in the active site 
of the full-length crystal structure (17).  Thus kinetic measurements may underestimate 
the proteolytic efficiency of full-length NS3, as autoinhibition would increase the 
apparent Km values.  Changes in apparent Km of T631C and T631N variants – designed 
to increase and decrease 3-4A product binding, respectively – would depend on the 
relative autoinhibition of the wildtype protein.  The presence of the helicase domain 
could alter the elementary rate constants, however, potentially confounding data 
interpretation compared to the protease domain alone.  Serine proteases exhibit two-step 
reaction mechanisms with covalently bound intermediates, and thus kcat and Km can 
represent various expressions depending on the rate-limiting step: 
 
Similar kinetic parameters of the protease domain and full-length protein may derive 
from different mathematical expressions of these elementary rate constants.  Pre-steady 
state kinetic studies are therefore necessary to rigorously differentiate catalytic 
differences between full-length NS3 and protease domain variants.
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 Other HCV Genotypes 
Though my research focuses on genotype 1a HCV, it also provides a blueprint for 
investigating drug efficacy against other HCV genotypes.  In particular, the NS3/4A 
protease of genotype 3a viruses, endemic in Southeast Asia (18), diverges considerably in 
primary sequence from genotype 1a strains.  Most notably, the protease contains 
threonine instead of arginine at residue 123, and glutamine instead of aspartate at residue 
168.  These residues participate in the electrostatic networks in many product complexes, 
and thus substantial mechanistic differences may exist in both substrate recognition and 
inhibitor binding.  In fact, telaprevir, boceprevir, danoprevir, vaniprevir and TMC-435 
exhibit markedly reduced activities against genotype 3 virus relative to other genotypes 
(19).  Structural and biochemical studies of substrate and drug binding should therefore 
be repeated for genotype 3 protease variants.  These genotypic differences will likely 
have important medical implications as protease inhibitors become integrated into anti-
HCV treatment regimens worldwide.
Targeting Other Rapidly Evolving Diseases 
Drug resistance arises from target mutations that selectively weaken inhibitor 
potency without significantly altering its natural biological function.  We observe that 
HCV and HIV resistance mutations arise where drugs protrude from the substrate 
envelope, as changes in these regions disrupt drug binding but not substrate recognition 
and cleavage (1, 20).  We can also define substrate envelopes in other disease systems 
whenever substrate interactions can be structurally characterized with drug targets.  
Potential systems include other Flaviviridae, such as Dengue, West Nile Virus and 
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 Yellow Fever, which encode serine proteases homologous to HCV NS3/4A (21-23).  The 
protozoan parasite causing malaria – Plasmodium falciparum – also encodes aspartyl 
proteases called plasmepsins (24, 25).  We can further expand our reach beyond the realm 
of protease enzymes.  The substrate envelope of influenzavirus A Neuraminidase – a 
glycoside hydrolase that cleaves neuraminic acids on infected cell surfaces – may 
facilitate the discovery of broadly acting neuraminidase inhibitors against diverse 
influenza serotypes.  Perhaps substrate envelope-based design approaches can someday 
help combat the emergence of drug resistance in other disease systems in the face of 
rapid disease evolution. 
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 CONCLUDING REMARKS 
The relevance of my research rests on the claim that drug resistance is a major 
obstacle in modern medicine.  Not all scientists share this view – opponents argue that 
combination therapies eliminate the likelihood of resistance altogether, as multiple drugs 
limit disease evolution through several distinct mechanisms simultaneously.  Indeed, this 
reasoning is sound and well supported for patients with the social, economic and 
logistical support necessary for strict treatment adherence.  Unfortunately, drug side 
effects, high cost and lacking social support often prevent patients from adhering to 
therapies.  In such instances, patients may routinely miss doses or fail to complete 
treatment regimens altogether.  Insufficient dosing causes pathogens to persist in patients, 
allowing for the evolution and selection of drug resistant strains.  Thus in the actual 
clinical setting, the acquisition of resistance challenges the long-term efficacy of most 
drugs – whether given as monotherapy or in combination.   
The emergence of drug resistance will continue until combination therapies 
comprise tolerable, accessible and affordable drugs that retain potency against broad 
spectrums of pathogen strains.  These are difficult challenges – drug tolerability, 
accessibility and affordability are often uncontrollable variables for basic scientists, and 
become matters of public health and social justice.  On the contrary, scientists have 
complete jurisdiction over optimizing drug potency in the face of evolving targets.  
Understanding the molecular underpinnings of resistance is therefore central to 
developing potent therapies against genetically diverse pathogen strains.  To this end, my 
research comprehensively defines the molecular basis of drug resistance against HCV 
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 NS3/4A protease inhibitors.  I ultimately hope my work helps generate more efficacious 
and tolerable anti-HCV therapies, and eventually serves to combat rising resistance in 
other infectious diseases causing human suffering throughout the world. 
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